WO2022138101A1 - 培養部材およびその用途 - Google Patents
培養部材およびその用途 Download PDFInfo
- Publication number
- WO2022138101A1 WO2022138101A1 PCT/JP2021/044665 JP2021044665W WO2022138101A1 WO 2022138101 A1 WO2022138101 A1 WO 2022138101A1 JP 2021044665 W JP2021044665 W JP 2021044665W WO 2022138101 A1 WO2022138101 A1 WO 2022138101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- culture
- cell
- medium
- differentiation
- Prior art date
Links
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 claims abstract description 124
- 229920000642 polymer Polymers 0.000 claims abstract description 50
- 238000012258 culturing Methods 0.000 claims abstract description 49
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000001301 oxygen Substances 0.000 claims abstract description 44
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 44
- 210000000056 organ Anatomy 0.000 claims abstract description 36
- 230000035699 permeability Effects 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 414
- 238000000034 method Methods 0.000 claims description 118
- 230000004069 differentiation Effects 0.000 claims description 85
- 230000002107 myocardial effect Effects 0.000 claims description 65
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 46
- 210000001519 tissue Anatomy 0.000 claims description 42
- 230000006698 induction Effects 0.000 claims description 35
- 230000001939 inductive effect Effects 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000004711 α-olefin Substances 0.000 claims description 10
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- 238000012136 culture method Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 description 102
- 210000001778 pluripotent stem cell Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 26
- 238000005259 measurement Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 18
- -1 ethylene, propylene, 1-butene Chemical class 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 150000001336 alkenes Chemical class 0.000 description 16
- 238000004659 sterilization and disinfection Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 210000004102 animal cell Anatomy 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 13
- 210000001988 somatic stem cell Anatomy 0.000 description 13
- 239000004793 Polystyrene Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229920002223 polystyrene Polymers 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 238000010899 nucleation Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 239000000853 adhesive Substances 0.000 description 8
- 230000001070 adhesive effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 8
- 238000005452 bending Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- ADOBXTDBFNCOBN-UHFFFAOYSA-N 1-heptadecene Chemical compound CCCCCCCCCCCCCCCC=C ADOBXTDBFNCOBN-UHFFFAOYSA-N 0.000 description 6
- GQEZCXVZFLOKMC-UHFFFAOYSA-N 1-hexadecene Chemical compound CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 6
- HFDVRLIODXPAHB-UHFFFAOYSA-N 1-tetradecene Chemical compound CCCCCCCCCCCCC=C HFDVRLIODXPAHB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000010724 Wisteria floribunda Nutrition 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadec-1-ene Chemical compound CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 description 6
- 239000002861 polymer material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 101150074995 MYL2 gene Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 4
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 4
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000003321 cartilage cell Anatomy 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 239000011147 inorganic material Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical compound CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1-dodecene Chemical compound CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 2
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 102000004903 Troponin Human genes 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012986 chain transfer agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 210000002336 epiblast cell Anatomy 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007613 slurry method Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229940106006 1-eicosene Drugs 0.000 description 1
- FIKTURVKRGQNQD-UHFFFAOYSA-N 1-eicosene Natural products CCCCCCCCCCCCCCCCCC=CC(O)=O FIKTURVKRGQNQD-UHFFFAOYSA-N 0.000 description 1
- RHUJMHOIQBDFQR-UHFFFAOYSA-N 2-[[3-(2-methoxyphenyl)-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]-n-(6-methyl-1,3-benzothiazol-2-yl)acetamide Chemical compound COC1=CC=CC=C1N1C(=O)C(SCC2)=C2N=C1SCC(=O)NC1=NC2=CC=C(C)C=C2S1 RHUJMHOIQBDFQR-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 1
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 1
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 1
- ZGSXEXBYLJIOGF-ALFLXDJESA-N IWR-1-endo Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2[C@H](C=C3)C[C@H]3[C@@H]2C1=O ZGSXEXBYLJIOGF-ALFLXDJESA-N 0.000 description 1
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 1
- 102000014021 KCNQ1 Potassium Channel Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102100030330 Myosin regulatory light chain 12B Human genes 0.000 description 1
- 101710092698 Myosin regulatory light chain 2 Proteins 0.000 description 1
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002600 TPX™ Polymers 0.000 description 1
- 229920005527 TPX™ MX001 Polymers 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940069096 dodecene Drugs 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010102 injection blow moulding Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000012968 metallocene catalyst Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000005488 sandblasting Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003623 transition metal compounds Chemical class 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000007666 vacuum forming Methods 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Definitions
- the present invention relates to a culture member and its use.
- spheroids obtained by culturing cells in three dimensions, which are different from conventional planar cell cultures, have been produced and are attracting attention. It has been reported that spheroids give results closer to living organisms than cells cultured in a plane in cell function evaluation and drug screening, and between in vitro and in vivo tests in drug discovery. It is expected to be an important tool to fill the gap.
- stem cells such as iPS cells are expected to be an important cell source for regenerative medicine and cell therapy, and it is required to prepare a large amount of high-quality cells.
- Patent Document 1 a method using a culture vessel whose surface has been processed or treated so as to inhibit cell adhesion (Patent Document 1), and a method of culturing in a floating state in a container having a resin layer having low cell adhesion.
- Patent Document 2 a method of forming spheroids in a state of adhering to the surface of the culture vessel by setting the adsorption amount of proteoglycan in the culture vessel to a specific value or more.
- a treatment in which the cells do not adhere to the surface of the culture vessel for example, the surface of the culture vessel is superhydrophilicized, made hydrophobic, or difficult to adhere. (Structure, etc.) is usually performed.
- the present invention has been made in view of the above circumstances, and an object of the present invention is to provide a culture member and a culture device capable of culturing cells and the like to form spheroids.
- an oxygen environment that is excellent in shape stability and suitable for culturing cells, tissues, or organs, does not emit autofluorescence, does not impair cell observability, and is a culture member and culture instrument that does not easily harbor drugs.
- the challenge is to provide.
- the present inventors have diligently studied to solve the above problems. As a result, it has been found that the above-mentioned problems can be solved by a culture member having the following constitution, and the present invention has been completed.
- the present invention is, for example, the following [1] to [12].
- a culture member for culturing cells, tissues, or organs on the culture surface the culture member contains 4-methyl-1-pentene polymer (X), and the water contact angle of the culture surface is 100.
- the 4-methyl-1-pentene polymer (X) is selected from 4-methyl-1-pentene, ethylene, and an ⁇ -olefin having 3 to 20 carbon atoms (excluding 4-methyl-1-pentene).
- [6] The culture member according to any one of [1] to [5], wherein the cell, tissue, or organ contains cardiomyocytes.
- [7] The culture member according to any one of [1] to [6], wherein the culture member has a film-like shape or a sheet-like shape.
- [8] A culture instrument in which at least the culture surface is formed of the culture member according to any one of [1] to [7].
- [9] A step (A) of bringing cells, tissues or organs into contact with the culture surface of the culture member according to any one of [1] to [7] or the culture device according to [8]; and on the culture surface.
- a method for culturing cells, tissues or organs comprising the step (B) of culturing contacted cells, tissues or organs to form spheroids.
- a step (C) of inducing the differentiation of the cells or the like is included, and the step (C) is a step of inducing the differentiation of iPS cells into myocardial cells by the protein-free myocardial differentiation induction (PFCD) method.
- PFCD protein-free myocardial differentiation induction
- the present invention it is possible to provide a culture member and a culture instrument capable of culturing cells and the like to form spheroids. Further, according to the present invention, an oxygen environment having excellent shape stability and suitable for culturing cells, tissues, or organs can be realized, autofluorescence is not emitted, cell observability is not impaired, and a drug is collected. It is possible to provide difficult culture members and culture equipment. Furthermore, according to the present invention, it is possible to provide a culture member and a culture instrument capable of culturing differentiated cells derived from stem cells in a state of high differentiated cell purity. In addition, the culture member and culture device of the present invention can easily differentiate iPS cells into cardiomyocytes.
- FIG. 1 is a diagram showing a schedule of an experiment for inducing differentiation of cardiomyocytes from iPS cells.
- FIG. 2 is a photograph of observing the morphology of cells on the 12th day of induction of myocardial differentiation.
- FIG. 3 is a photograph of observing the morphology of cells on the 19th day of induction of myocardial differentiation.
- FIG. 4 is a photograph of the human osteosarcoma-derived cancer cells (HOF-143B) of Example 3 observing the formation of spheroids.
- HAF-143B human osteosarcoma-derived cancer cells
- the culture member according to the present invention is a member for culturing cells, tissues or organs (hereinafter, also referred to as cells) on the culture surface, and the culture member contains 4-methyl-1-pentene polymer (X).
- the water contact angle of the culture surface is larger than 100 ° and 160 ° or less, and the oxygen permeability when the temperature is 23 ° C and the humidity is 0% is 4500 to 90000 cm 3 / (m 2 ⁇ 24 h ⁇ atm).
- the culture member means a member that constitutes at least a part of a culture instrument used for culturing cells and the like.
- the culture surface means a surface on which a medium is formed, a surface on which cells or the like are seeded, or a surface on which a medium is formed and cells or the like are seeded when the cells or the like are cultured. That is, the culture surface is a concept including a medium formation schedule surface and a seeding schedule surface such as cells.
- culture is used in a broad sense including not only the proliferation and maintenance of cells and the like, but also the processes of seeding, passage, differentiation induction, self-organization induction of cells and the like.
- the form of the culture member of the present invention is not particularly limited, and may be, for example, a film or a sheet.
- the culture member When the culture member is in the form of a film or a sheet, it can be suitably used as a culture instrument in which at least one surface of the film-shaped or sheet-shaped culture member is used as a culture surface.
- the culture member of the present invention means that the culture surface is not coated with a natural polymer material, a synthetic polymer material, or an inorganic material for serving as a scaffold for cells or the like.
- the thickness of the culture member of the present invention is not particularly limited.
- the thickness of the culture member of the present invention is not particularly limited, but is preferably 20 to 500 ⁇ m, more preferably 25 to 400 ⁇ m, and particularly preferably 50 to 200 ⁇ m.
- an appropriate oxygen concentration in the medium necessary for cell growth can be obtained, and a suitable culture instrument can be prepared without bending the culture member, particularly the bottom surface of the culture container. It will be easier to do.
- the thickness of the culture member when the culture member of the present invention is arranged on the bottom surface of the container to prepare a culture device such as a dish (also referred to as a petri dish), a flask, an insert or a plate is not particularly limited, but is preferably 20 ⁇ m to 400 ⁇ m.
- the thickness is more preferably 20 ⁇ m to 300 ⁇ m, still more preferably 20 ⁇ m to 200 ⁇ m.
- the thickness of the culture member is appropriately selected according to the morphology of the culture device, but by adjusting the thickness to the above range, it is easy to obtain an appropriate oxygen concentration in the medium necessary for cell growth, and sufficient strength is obtained. It becomes easy to produce a suitable culture medium to have.
- the surface of the culture member of the present invention may be processed as long as the effect of the present invention is not impaired.
- Examples of the surface processing include surface modification treatment such as formation processing of uneven structure, hydrophilization treatment, and hydrophobic treatment.
- the surface of the culture member of the present invention cells can hardly adhere to each other without processing the surface thereof, so that spheroids can be formed. Therefore, it is preferable that the surface of the culture member of the present invention is not processed, and it is more preferable that the surface of the culture member is not processed to form an uneven structure.
- the method used for the surface modification treatment is not particularly limited, and is, for example, hydrophilization treatment such as corona treatment, plasma treatment, ozone treatment, and ultraviolet treatment, hydrophobic treatment such as esterification, silylation, and fluorination, surface graft polymerization, and chemistry. Evaporation, etching, addition of specific functional groups such as hydroxyl group, amino group, sulfone group, thiol group, carboxyl group, treatment with specific functional groups such as silane coupling, titanium coupling, zirconium coupling, oxidizing agent Surface roughening due to the above, physical treatment such as rubbing and sandblasting, etc. can be mentioned. These surface modification treatments may be performed alone or in combination of two or more. When the surface modification treatment is performed, it is preferable to perform the surface modification treatment at least on the culture surface.
- the method for producing the culture member of the present invention is not particularly limited, and the equipment used for production is not limited.
- the equipment used for production is not limited.
- the film, sheet or other molded product to be a culture member can also be obtained by direct molding by a method such as extrusion molding, solution cast molding, injection molding or blow molding.
- the extrusion temperature is preferably 100 ° C. to 400 ° C., particularly preferably 200 ° C. to 300 ° C.
- the roll temperature is preferably 45 ° C to 75 ° C, particularly preferably 55 ° C to 65 ° C.
- the film or sheet is manufactured by a solution casting method in which 4-methyl-1-pentene polymer (X) is dissolved in a solvent, poured onto a resin or metal, and slowly dried while leveling to form a film (sheet).
- the solvent used is not particularly limited, but a hydrocarbon solvent such as cyclohexane, hexane, decane, or toluene may be used. Further, as the solvent, two or more kinds may be mixed in consideration of the solubility and the drying efficiency of the 4-methyl-1-pentene polymer (X).
- the polymer solution can be applied by a method such as table coat, spin coat, dip coat, die coat, spray coat, bar coat, roll coat, curtain flow coat, etc., dried and peeled off to form a film or sheet.
- the culture member of the present invention is preferably a spheroid-forming culture member, and more preferably a spheroid-forming cell culture member.
- 4-methyl-1-pentene homopolymer and copolymer of 4-methyl-1-pentene and other monomers are collectively referred to as "4-methyl-1-pentene polymer (X)".
- Examples of the copolymer of 4-methyl-1-pentene, which is an example of 4-methyl-1-pentene polymer, and other monomers include random copolymers, alternating copolymers, block copolymers, and grafts. It may be any of the copolymers.
- the copolymers of 4-methyl-1-pentene and other monomers include 4-methyl-1-pentene, ethylene, and ⁇ -olefins having 3 to 20 carbon atoms (excluding 4-methyl-1-pentene). ), A copolymer with at least one olefin selected from) is preferable because it has high strength, is hard to tear even when used as a member, is hard to crack, and has little bending.
- the 4-methyl-1-pentene polymer examples include 4-methyl-1-pentene homopolymer, 4-methyl-1-pentene, ethylene and ⁇ -olefin having 3 to 20 carbon atoms (4-methyl-1). -Preferably, it is at least one polymer selected from a polymer selected from a polymer with at least one olefin selected from (excluding pentene), preferably 4-methyl-1-pentene, ethylene and 3 to 20 carbon atoms. It is more preferable that the polymer is a copolymer with at least one olefin selected from ⁇ -olefins (excluding 4-methyl-1-pentene).
- olefin examples include ethylene, propylene, 1-butene, 1-hexene, 1-heptene, 1-octene, 1-decene, 1-tetradecene, 1-hexadecene, 1-heptadecene, 1-octadecene and 1-eicosene. Can be mentioned.
- the olefin can be appropriately selected depending on the physical characteristics required for the culture member.
- ⁇ -olefin having 8 to 18 carbon atoms is preferable from the viewpoint of appropriate oxygen permeability and excellent rigidity, and 1-octene, 1-decene, 1-dodecene, 1-tetradecene, At least one selected from 1-hexadecene, 1-heptadecene and 1-octadecene is more preferred.
- the carbon number of the olefin is in the above range, the processability of the polymer becomes better, and the appearance of the culture member is less likely to be deteriorated due to cracks or cracks at the ends. In addition, the rate of defective products in the culture member is low.
- the olefin may be used alone or in combination of two or more.
- the number of carbon atoms is preferably 2 or more, more preferably 10 or more.
- the content of the structural unit derived from 4-methyl-1-pentene in the 4-methyl-1-pentene polymer is preferably 60 to 100 mol%, more preferably 80 to 98 mol%.
- the 4-methyl-1-pentene polymer is at least one selected from 4-methyl-1-pentene, ethylene and ⁇ -olefin having 3 to 20 carbon atoms (excluding 4-methyl-1-pentene).
- it is a copolymer with an olefin
- it is derived from at least one olefin selected from ethylene in the copolymer and ⁇ -olefin having 3 to 20 carbon atoms (excluding 4-methyl-1-pentene).
- the content of the structural unit is preferably 0 to 40 mol%, more preferably 2 to 20 mol%.
- the content of these structural units is 100 mol% based on the total amount of repeated structural units in the 4-methyl-1-pentene polymer.
- the 4-methyl-1-pentene polymer is derived from the structural unit derived from 4-methyl-1-pentene and the ethylene and ⁇ -olefin having 3 to 20 carbon atoms to the extent that the effect of the present invention is not impaired. It may have a structural unit other than the structural unit (hereinafter, also referred to as “other structural unit”). The content of the other structural units is, for example, 0 to 10.0 mol%. When the 4-methyl-1-pentene polymer has other structural units, the other structural units may be one kind or two or more kinds.
- Examples of the monomer leading to other structural units include cyclic olefins, aromatic vinyl compounds, conjugated dienes, non-conjugated polyenes, functional vinyl compounds, hydroxyl group-containing olefins, and halogenated olefins.
- Examples of the cyclic olefin, aromatic vinyl compound, conjugated diene, non-conjugated polyene, functional vinyl compound, hydroxyl group-containing olefin and halogenated olefin are described in paragraphs [0035] to [0041] of JP2013-169685A. Compounds can be used.
- the 4-methyl-1-pentene polymer may be used alone or in combination of two or more.
- 4-methyl-1-pentene polymer Commercially available products can also be used as the 4-methyl-1-pentene polymer. Specific examples thereof include TPX MX001, MX002, MX004, MX0020, MX021, MX321, RT18, RT31 and DX845 manufactured by Mitsui Chemicals, Inc.). Further, a 4-methyl-1-pentene polymer that satisfies the above requirements can be preferably used even if it is manufactured by another manufacturer. These commercially available products may be used alone or in combination of two or more.
- the 4-methyl-1-pentene polymer usually has a melting point of 200 ° C. to 240 ° C. and has high heat resistance.
- culture members such as culture instruments containing 4-methyl-1-pentene polymer can be subjected to high-pressure steam sterilization treatment.
- the 4-methyl-1-pentene polymer also has a high visible light transmittance (usually 90% or more) and does not emit autofluorescence, a culture instrument containing the 4-methyl-1-pentene polymer is cultured. Easy to observe cells.
- it exhibits excellent chemical resistance to most chemicals and it is difficult for the chemicals to be collected it is also suitably used for drug discovery screening applications and diagnostic applications.
- the 4-methyl-1-pentene polymer can be heat-sealed, and not only heat fusion between own materials but also heat adhesion with other materials is easy. Further, since thermoforming is possible, it is easy to mold into a culture instrument having an arbitrary shape, and for example, molding using an imprint method or an insert method is also easy.
- the weight average molecular weight (Mw) of 4-methyl-1-pentene polymer measured by gel permeation chromatography (GPC) using standard polystyrene as a reference material is preferably 10,000 to 2000000, more preferably 20000. It is up to 1,000,000, more preferably 30,000 to 500,000.
- the sample concentration at the time of GPC measurement can be, for example, 1.0 to 5.0 mg / ml.
- the molecular weight distribution (Mw / Mn) of the 4-methyl-1-pentene polymer is preferably 1.0 to 30, more preferably 1.1 to 25, and even more preferably 1.1 to 20.
- orthodichlorobenzene is preferably used as the solvent used in GPC.
- the conditions shown in the examples described later can be mentioned, but the measurement conditions are not limited to the measurement conditions.
- the film produced by melt molding can easily suppress the occurrence of defects such as gel. It is easy to form a film with a uniform surface. Further, when the film is produced by the solution casting method, the solubility in a solvent is improved, defects such as gel of the film can be easily suppressed, and a film having a uniform surface can be easily formed.
- the strength of the culture member tends to be sufficient. Furthermore, by keeping the molecular weight distribution within the above range, stickiness on the surface of the produced culture member tends to be suppressed, the toughness of the culture member tends to be sufficient, and bending during molding and cracking during cutting tend to occur. It becomes easier to suppress.
- the weight average molecular weight (Mw) and molecular weight distribution (Mw / Mn) of the 4-methyl-1-pentene polymer are different when two or more kinds are used as the 4-methyl-1-pentene polymer. , Mw and Mw / Mn may be in the above range.
- the 4-methyl-1-pentene polymer has the above-mentioned excellent properties, at least the culture device in which the culture surface is formed of the culture member of the present invention does not adversely affect the culture. In addition, it has good stability, light transmission, and moldability, and can be sterilized, so that it is very excellent as a material for culture members.
- the method for producing the 4-methyl-1-pentene polymer may be any method as long as 4-methyl-1-pentene, an olefin, or another monomer can be polymerized. Further, a chain transfer agent such as hydrogen may coexist in order to control the molecular weight and the molecular weight distribution.
- the equipment used for manufacturing is also not limited.
- the polymerization method may be a known method, or may be a vapor phase method, a slurry method, a solution method, or a bulk method. The slurry method and the solution method are preferable.
- the polymerization method may be a single-stage polymerization method or a multi-stage polymerization method such as a two-stage polymerization method, in which a plurality of polymers having different molecular weights are blended into the polymerization system.
- a single-stage polymerization method when hydrogen is used as the chain transfer agent, it may be charged all at once or dividedly, for example, at the initial stage, middle stage, or final stage of polymerization.
- the polymerization may be carried out at room temperature or may be heated if necessary, but from the viewpoint of polymerization efficiency, it is preferably carried out at 20 ° C to 80 ° C, and particularly preferably at 40 ° C to 60 ° C. ..
- the catalyst used for production is also not limited, but from the viewpoint of polymerization efficiency, for example, the solid titanium catalyst component (I) described in International Publication Publication 2006/054613 and the transition metal compound described in International Publication Publication No. 2014/050817 It is preferable to use a catalyst for olefin polymerization (metallocene catalyst) containing (A).
- the 4-methyl-1-pentene polymer (X) is contained in 100% by mass of the culture member. It is preferably 90% by mass or more and less than 100% by mass, more preferably 95% by mass or more and less than 100% by mass, and particularly preferably 99% by mass or more and less than 100% by mass. If a large amount of a component other than the 4-methyl-1-pentene polymer (X) is contained, not only the oxygen permeability is lowered, but also the transparency and the strength are lowered.
- the material forming the culture member of the present invention may contain components other than the 4-methyl-1-pentene polymer (X).
- Ingredients other than 4-methyl-1-pentene polymer (X) include heat-resistant stabilizers, light-resistant stabilizers, processing aids, plasticizers, antioxidants, lubricants, defoamers, anti-blocking agents, and coloring agents. Additives such as agents, modifiers, antibacterial agents, antifungal agents, antifoaming agents and the like can be mentioned.
- the culture member of the present invention has a water contact angle of the culture surface of more than 100 ° and 160 ° or less.
- the water contact angle is preferably larger than 100 ° and 150 ° or less, more preferably larger than 100 ° and 130 ° or less, and further preferably larger than 105 ° and 130 ° or less.
- the water contact angle of the culture surface of the culture member is 100 ° or less, cells and the like adhere to the culture member, and it is difficult to form spheroids.
- the water contact angle of the culture surface of the culture member is larger than 160 °, the contact between the culture surface and the medium becomes insufficient, and the oxygen supply efficiency into the medium is lowered.
- the method for measuring the water contact angle is not particularly limited, and a known method can be used, but the static drip method is preferable.
- the water contact angle can be regarded as a spherical shape under constant temperature and humidity conditions of 25 ⁇ 5 ° C. and 50 ⁇ 10%, for example, according to the Japanese Industrial Standard JIS-R3257 (wetness test method for the substrate glass surface).
- a water droplet having a volume of 4 ⁇ L or less is dropped on the surface of the measurement sample prepared using the culture member or the same material as the culture member, and within 1 minute immediately after the water droplet comes into contact with the surface of the measurement sample by the static drip method. It can be measured by a method of measuring the angle of the contact interface between the measurement sample and the water droplet.
- the oxygen permeability of the culture member of the present invention at a temperature of 23 ° C. and a humidity of 0% is 4500 to 90000 cm 3 / (m 2 ⁇ 24 h ⁇ atm), preferably 4500 to 67500 cm 3 / (m 2 ⁇ 24 h ⁇ ). Atm), more preferably 4500 to 47000 cm 3 / (m 2 ⁇ 24 h ⁇ atm), and even more preferably 4500 to 45000 cm 3 / (m 2 ⁇ 24 h ⁇ atm).
- the oxygen permeability of the culture member is too low, the oxygen concentration in the medium will be low and the cells will not grow sufficiently. On the other hand, if the oxygen permeability is too high, the oxygen concentration in the medium becomes too high, and the cell function deteriorates due to oxygen stress. When the oxygen permeability is within the upper and lower limits, the cells can maintain good morphology and proliferate efficiently according to the culture period.
- the device used for the measurement is not particularly limited as long as it uses the differential pressure type gas permeability measuring method, and examples thereof include the differential pressure type gas permeability measuring device MT-C3 manufactured by Toyo Seiki Seisakusho.
- the measurement sample is preferably prepared by cutting out a 90 ⁇ 90 mm test piece from, for example, a film having a thickness of 50 ⁇ m, and the diameter of the measurement portion is 70 mm (transmission area is 38.46 cm 2 ). Since the oxygen permeability is high, it is more preferable to apply an aluminum mask to the sample in advance so that the actual permeation area is 5.0 cm 2 .
- the culture member used for measuring the oxygen permeability or the measurement sample prepared using the same material as the culture member may or may not have undergone microfabrication or surface modification treatment. It is preferable that the product has not been treated.
- cells, tissues, or organs are also simply referred to as "cells, etc.”
- the origin of cells and the like is not particularly limited and may be any organism such as animals, plants, insects, fungi, protists and bacteria, but animals or plants are preferable, animals are more preferable, and mammals are particularly preferable. Since the culture member of the present invention can be cultured while avoiding adhesion of cells and the like and has excellent oxygen permeability, it is preferable that the cells and the like are non-adhesive.
- the cell in the present invention is not particularly limited, and examples thereof include plant cells, animal cells, insect cells and the like, but animal cells are preferable, and mammalian cells are more preferable.
- the mammalian cells cells derived from humans, monkeys, mice, rats, pigs, dogs, sheep, cats and goats are preferable, and cells derived from humans are more preferable.
- the cell may be a cell cultured in two dimensions or a cell cultured in three dimensions, and contains a spheroid obtained by culturing the cell.
- frozen or re-frozen cells may be used.
- the cells in the present invention may be passaged cells, and the number of passages is not particularly limited.
- animal cells normal cells, cancer cells, fusion cells such as hybridomas and the like can be used, and cells that have been artificially treated such as gene transfer may be used.
- the animal cell may be either a primary cultured cell or a cell that has been passaged to a strain.
- Animal cells may be floating cells or adhesive cells.
- Animal cells include, for example, undifferentiated pluripotent stem cells, differentiated cells derived from pluripotent stem cells (including pluripotent stem cells that have started to induce differentiation and are already in the process of differentiation), and undifferentiated somatic stem cells. , Differentiated cells derived from somatic stem cells (including somatic stem cells that have started to induce differentiation and are already in the process of differentiation), and differentiated cells derived from animal tissues.
- the differentiated cells are not limited to cells that have matured to the final stage of differentiation (finally differentiated mature cells).
- the differentiated cell may be a cell that differentiates and matures from the ectoderm, a cell that differentiates and matures from the middle germ layer, or a cell that differentiates and matures from the endoderm.
- Pluripotent stem cells are cells that have pluripotency that can differentiate into all the cells that make up the living body and self-renewal ability that can maintain that pluripotency even after cell division. Means.
- the pluripotent stem cells include embryonic stem cells (ES cells), embryonic germ cells (EG cells), induced pluripotent stem cells (iPS cells), and muse cells (iPS cells).
- Multi-lineage differing Strength Enduring cell embryonic stem cell (EC cell), embryonic stem cell (TS cell), embryonic stem cell (TS cell), epiblast cell (TS cell), and epiblast cell (TS cell).
- Pluripotent stem cells are preferably ES cells or iPS cells, more preferably iPS cells.
- ES cells can be established by removing the inner cell mass from the blastocyst of a fertilized mammalian egg and culturing the inner cell mass on a fibroblast feeder. For cell maintenance by subculture, use a culture medium supplemented with substances such as leukemia inhibitory factor (LIF) and basic fibroblast growth factor (bFGF). It can be carried out.
- LIF leukemia inhibitory factor
- bFGF basic fibroblast growth factor
- WA01 (H1) and WA09 (H9) are from the WiCell Research Institute, and KhES-1, KhES-2 and KhES-3 are from the Institute for Frontier Medical Sciences, Kyoto University (Kyoto, Japan). It is available from.
- iPS cells can be produced by introducing specific reprogramming factors into somatic cells in the form of DNA or protein (K. Takahashi and S. Yamanaka (2006) Cell, 126: 663-676; K. Takahashi et al. (2007), Cell, 131: 861-872; J. Yu et al. (2007), Science, 318: 1917-1920; Nakagawa, M. et al., Nat. Biotechnol. 26: 101-106 ( 2008); International release WO 2007/069666).
- the somatic cell means any animal cell (preferably a mammalian cell including human) except for germline cells such as eggs, egg mother cells, ES cells or pluripotent cells of differentiation, and is a somatic cell of a fetal (pup).
- Neonatal (pup) somatic cells and mature healthy or diseased somatic cells, as well as primary cultured cells, passaged cells, and established cells.
- tissue stem cells such as nerve stem cells, hematopoietic stem cells, mesenchymal stem cells, and dental pulp stem cells
- tissue precursor cells lymphocytes, epithelial cells, endothelial cells, muscle cells, and fibroblasts.
- the reprogramming factor is a gene specifically expressed in ES cells, its gene product or non-coding RNA, or a gene that plays an important role in maintaining undifferentiated ES cells, its gene product or non-coding RNA, Alternatively, it may be composed of a low molecular weight compound.
- Genes contained in the reprogramming factor include, for example, Oct3 / 4, Sox2, Sox1, Sox3, Sox15, Sox17, Klf4, Klf2, c-Myc, N-Myc, L-Myc, Nanog, Lin28, Fbx15, Eras, ECAT15. -2, Tcl1, beta-catenin, Lin28b, Sall1, All4, Esrrb, Nr5a2, Tbx3, Glis1, etc. These initialization factors may be used alone or in combination of two or more. May be.
- a somatic stem cell means a cell having a limited differentiation ability capable of differentiating into a specific cell and a self-renewal ability capable of maintaining the limited differentiation ability even through cell division.
- Somatic stem cells include mesenchymal stem cells, hematopoietic stem cells, neural stem cells and the like.
- Differentiated cells derived from animal tissues include, for example, fat cells, hepatocytes, renal cells, pancreatic cells, mammary gland cells, endothelial cells, epithelial cells, smooth muscle cells, myoblasts, and myocardial cells, including various precursor cells. , Nerve cells, glial cells, dendritic cells, cartilage cells, osteoblasts, osteoclasts, bone cells, fibroblasts, various blood lineage cells, retinal cells, corneal cells, germ gland-derived cells, various line cells, etc. Can be mentioned.
- the cells may be used alone or in combination of two or more.
- animal cells are suitable for spheroid formation, they are preferably pluripotent stem cells and differentiated cells derived from pluripotent stem cells, more preferably iPS cells and differentiated cells derived from iPS cells, and more preferably myocardium derived from iPS cells. It is a cell, particularly preferably a human myocardial cell derived from an iPS cell.
- animal cells are preferably somatic stem cells, more preferably mesenchymal stem cells, as they are suitable for spheroid formation.
- animal cells are preferably cancer cells because they are suitable for spheroid formation.
- animal cells are preferably cells that are generally required to be three-dimensionally cultured, and more preferably spheroids, because the state of the cells can be brought closer to the state in the living body having a three-dimensional structure.
- the cells that form, for example, hepatocytes, nerve cells, myocardial cells, pancreatic ⁇ cells, vascular endothelial cells, fat cells, adipose-derived stem cells, cartilage cells, mesenchymal stem cells, hair follicle epithelial stem cells, hair papilla cells, Skin fibroblasts, skin keratinized cells, and osteoblasts.
- the animal cell when the animal cell is a differentiated cell derived from a pluripotent stem cell, the cell can be produced from the pluripotent stem cell by a known differentiation induction method. Alternatively, commercially available differentiated cells derived from pluripotent stem cells may be used. When the animal cells are somatic stem cells, those collected from animals may be used, or commercially available cells may be used.
- the differentiated cells derived from pluripotent stem cells are preferably cardiomyocytes derived from iPS cells.
- Cardiomyocytes derived from iPS cells can be produced, for example, by a known protein-free myocardial differentiation induction (PFCD) method (see International Publication No. 2015/182765). Since the protein-free myocardial differentiation induction (PFCD) method can achieve high myocardial differentiation efficiency, the iPS cell-derived cardiomyocytes produced by the method can achieve high cardiomyocyte purity.
- PFCD protein-free myocardial differentiation induction
- the spheroid refers to a mass of cells gathered together, and can be paraphrased as a cell aggregate or a cell mass.
- the spheroid may be a spheroid containing a single cell such as a cardiomyocyte, or a spheroid containing two or more different cell types such as various fibroblasts, vascular endothelial cells and the like and cardiomyocytes. Examples of cells that can be used include the above-mentioned various cells.
- the spheroid formed by using the culture member or the culture instrument of the present invention is preferably a spheroid containing pluripotent stem cells and a spheroid containing differentiated cells derived from pluripotent stem cells, and more preferably a spheroid containing iPS cells or It is a spheroid containing differentiated cells derived from iPS cells, and more preferably a spheroid containing myocardial cells derived from iPS cells.
- the spheroid is preferably 10% or more, more preferably 13% or more, further preferably 15% or more, still more preferably 20% or more, and particularly preferably 30% or more of differentiated cell purity (number of differentiated cells / cells constituting the spheroid). It has a number ⁇ 100).
- the spheroids are preferably 10% or more, more preferably 20% or more, still more preferably 30% or more of cardiomyocytes derived from iPS cells. Includes in cardiomyocyte purity.
- the number of differentiated cells can be determined by a known method, and for example, myocardial markers such as myocardial troponin T (cTnT), Troponin, MYL2 (Myosin regutry light chain 2), MYL7 (Myosin regutory light chain 7), and the like. It can be obtained by analysis by flow cytometry using.
- the number of cells constituting the spheroid can be determined by a known method. For example, the spheroid can be determined by Trypsin treatment to make it into a single cell and measuring the number of cells in the single cell.
- the finally obtained spheroids include undifferentiated cells and cells differentiated other than the desired differentiated cells in addition to the target differentiated cells. Not a little included. Therefore, when the purity of the differentiated cells is within the above range, the reliability of the data when the spheroids of the differentiated cells are used for various tests is high, and the reproducibility is likely to be high.
- the size of the spheroid is not particularly limited. Although it varies depending on the cell type, the number of cells, the medium, the number of culture days, etc. that form the spheroid, the size of the spheroid preferably has an average diameter of, for example, 10 to 10000 ⁇ m, more preferably 10 to 8000 ⁇ m, and 10 to 5000 ⁇ m. Is more preferable.
- the diameter of the spheroid can be determined, for example, by a method of observing under a microscope and measuring the diameter on a photograph taken, or a method using a particle size distribution meter.
- the number of cells constituting the spheroid is not particularly limited. Depending on the cell type, medium, culture days, etc. that form the spheroid, for example, 1 ⁇ 10 1 or more, 1 ⁇ 10 2 or more, 1 ⁇ 10 3 or more, 1 ⁇ 10 4 or more, per spheroid, It may contain 1 ⁇ 10 5 or more, 1 ⁇ 10 6 or more, 1 ⁇ 10 7 or more, 1 ⁇ 10 8 or more, and 1 ⁇ 10 9 or more. The upper limit is not set in particular.
- the number of cells constituting the spheroid can be calculated, for example, from the fluorescence intensity after cell staining with a fluorescent reagent and the calibration curve of the number of cells and the fluorescence intensity.
- the medium used for cell culture may be appropriately selected according to the cells.
- the type of medium is not particularly limited, but for example, any cell culture basic medium, differentiation medium, primary culture-dedicated medium, or the like can be used. Specifically, Essential8, Eagle's Small Essential Medium (EMEM), Dalveco Kai Eagle's Medium (DMEM), ⁇ -MEM, Glasgow MEM (GMEM), IMDM, RPMI1640, Ham F-12, MCDB Medium, Williams Medium E, Hepatocyte Examples thereof include the medium and a mixed medium thereof, but the medium is not limited to these, and any medium containing components necessary for cell proliferation and differentiation can be used.
- a medium containing serum, various growth factors, differentiation-inducing factors, antibiotics, hormones, amino acids, sugars, salts and the like may be used.
- the culture temperature is not particularly limited, but is usually about 25 to 40 ° C.
- the amount of the medium is not particularly limited, but the height of the medium is preferably 3 to 30 mm, more preferably 3 to 25 mm, still more preferably 4 to 20 mm.
- the tissue in the present invention means a group of similar cells that have the same function, and is a concept different from that of spheroids.
- the tissue is not particularly limited, and examples thereof include epithelial tissue, connective tissue, muscle tissue, and nervous tissue.
- the tissue is preferably a tissue containing cells forming spheroids, and examples of such tissues include nerve tissue containing nerve cells, myocardial tissue containing myocardial cells, adipose tissue containing adipose cells or adipose-derived stem cells, and cartilage. Examples thereof include cartilage tissue containing cells, bone tissue containing osteoblasts, and the like.
- the tissue is preferably a nerve tissue or a myocardial tissue, and a myocardial tissue is more preferable.
- the tissue is suitable for spheroid formation, it is preferably a tissue containing somatic stem cells.
- the organ in the present invention means an organ in which the tissues gather and perform a joint work with a purpose.
- the organ is not particularly limited, and is, for example, lung, heart, liver, kidney, spleen, pancreas, gallbladder, esophagus, stomach, skin, brain and the like.
- the organ is preferably an organ containing cells forming spheroids, and such organs include, for example, a liver containing hepatocytes, a pancreas containing pancreatic ⁇ cells, a blood vessel containing vascular endothelial cells, and mesenchymal stem cells.
- Examples include bone marrow, hair follicles containing hair follicular epithelial stem cells or hair papilla cells, kidneys, skin containing skin fibroblasts or skin keratinized cells, and the like.
- the organs are preferably skin, kidney, liver, pancreas, heart, and hair follicles, and more preferably the heart, because of the high oxygen requirement.
- the organ is suitable for spheroid formation, it is preferably an organ containing somatic stem cells.
- the culture instrument means all instruments used for culturing cells and the like. At least a part of the culture instrument is composed of the culture member.
- the culture instrument may be entirely composed of the culture member, or only a part thereof may be composed of the culture member.
- the culture surface for culturing at least cells and the like is composed of the culture member of the present invention.
- the culture device is usually used in an device such as an incubator, a mass culture device, or a perfusion culture device.
- the culture device various known culture tools can be used, and the shape and size are not particularly limited.
- the culture instrument include culture containers such as dishes, flasks, plates, bottles, bags, and tubes, as well as inserts, cups, insoles, slides, and the like, and are preferably culture vessels.
- the culture instrument may be a culture instrument having at least one well or a culture vessel having at least one well.
- a culture vessel having at least one well is, for example, a plate having at least one well, more specifically 6 wells, 12 wells, 24 wells, 48 wells, 96 wells, 384 wells, 1536 wells and the like. It is a plate with a well.
- a culture device having a hollow shape like a well on the bottom surface it is necessary to make the bottom surface thick in order to stabilize the complicated shape of the bottom surface, and it is difficult to sufficiently supply oxygen to cells and the like.
- the shape is stable even in a plate having wells such as 1 well, 6 wells, 12 wells, 24 wells, 48 wells, 96 wells, 384 wells, and 1536 wells. Sufficient oxygen supply to cells and the like.
- the culture device is preferably a device whose bottom surface is a culture surface in order to hold or store the medium.
- the culture instrument is a dish, a flask, an insert, or a plate
- the bottom surface is the culture surface, so that the culture member of the present invention constitutes at least a part or all of the bottom surface, the side surface, and the top surface. It is preferable to do so.
- at least the bottom surface (culture surface) is composed of the culture member of the present invention, oxygen can be more efficiently supplied to the medium through the culture member, and cells and the like in the medium can be proliferated more efficiently. be able to.
- it can be cultured at a higher density while maintaining the function of the cells.
- the shape of the bottom surface of the incubator is not particularly limited, and examples thereof include a flat bottom, a round bottom (U bottom), a flat bottom (F bottom), a conical bottom (V bottom), and a flat bottom + curved edge.
- a round bottom (U bottom), flat bottom (F bottom), conical bottom (V bottom), flat bottom + curved edge, etc. it may be processed at once by general injection molding or press molding, or a film. Alternatively, it is also possible to prepare a sheet and perform secondary processing by vacuum forming, pressure forming, or the like.
- the shape of the bottom surface is selected according to the purpose of the culture, but when culturing cells or the like in two dimensions, it is usually desirable to have a flat bottom, and when culturing in three dimensions, a round bottom (U bottom) or a cone. It is usually desirable to have a bottom (V bottom).
- the part of the culture instrument other than the culture member may be made of a material other than the culture member.
- the material other than the culture member is not particularly limited, and a known material can be used. Examples of such materials include polystyrene, polydimethylsiloxane (PDMS), cyclic olefin polymers, cyclic olefin copolymers, glass and the like.
- the culture instrument may be used after coating the culture surface and / or a portion other than the culture surface with a natural polymer material, a synthetic polymer material, or an inorganic material.
- a natural polymer material e.g., polyethylene glycol
- a synthetic polymer material e.g., polyethylene glycol
- an inorganic material e.g., polyethylene glycol
- the presence or absence of coating on the culture surface can be determined according to the type of cells and the like, but it is usually preferable not to coat the culture surface.
- the culture device of the present invention may be disinfected or sterilized to prevent contamination.
- the method of disinfection or sterilization is not particularly limited, and is a physical disinfection method such as a circulating steam method, a boiling method, an intermittent method, an ultraviolet method, a gas such as ozone, or a chemical disinfection method using a disinfectant such as ethanol; Heat sterilization methods such as high-pressure steam method and dry heat method; irradiation sterilization methods such as gamma ray method, electron beam method, and high frequency method; gas sterilization methods such as ethylene oxide gas method and ozone hydrogen gas plasma method can be mentioned.
- the ethanol disinfection method, the high-pressure steam sterilization method, the gamma ray sterilization method, the electron beam sterilization method, or the ethylene oxide gas sterilization method is preferable because the operation is simple and the sterilization can be sufficiently performed.
- These disinfection or sterilization treatments may be performed individually by 1 type or in combination of 2 or more types.
- the method for producing the culture instrument of the present invention is not particularly limited, and when the entire culture instrument is composed of the culture member, it can be produced by the same method as the method for producing the culture member.
- the culture instrument can be obtained by appropriately joining the culture member and the other member.
- the method of joining is not particularly limited, and the culture member and other members may be integrally formed, or may be brought into close contact with each other via an adhesive or an adhesive.
- the culture device of the present invention is preferably a spheroid-forming culture device, and more preferably a spheroid-forming cell culture device.
- the method for culturing cells and the like of the present invention is a culture member for culturing cells, tissues, or organs on the culture surface thereof, and the culture member contains 4-methyl-1-pentene polymer (X) and is the culture.
- a culture member having a surface water contact angle greater than 100 ° and 160 ° or less and an oxygen permeability of 4500-90000 cm 3 / (m 2 x 24 h x atm) at a temperature of 23 ° C and a humidity of 0%, or at least.
- the culture method of the present invention is that when cells or the like are cultured on the culture surface of the culture member or the culture instrument, the cells or the like can efficiently form spheroids. Further, according to the present invention, pluripotent stem cells can be easily differentiated into differentiated cells efficiently.
- the method of contacting the cells or the like with the culture surface of the culture member or the culture instrument is not particularly limited as long as the cells or the like can be brought into contact with the culture surface of the culture member or the culture instrument, and for example, the culture surface of the culture member or the culture instrument. Seeding cells and the like can be mentioned. More specifically, for example, cells suspended in a medium are added into a culture vessel with a pipette or the like, and if necessary, the culture vessel is shaken to evenly disperse the cells in the culture vessel. Let stand in the incubator.
- the density at which cells and the like are seeded is not particularly limited as long as the cells and the like can proliferate and differentiate.
- the seeding density is preferably 0.1 ⁇ 10 5 cells / cm 2 to 10.0 ⁇ 10 5 cells /. It is cm 2 , more preferably 0.3 ⁇ 10 5 cells / cm 2 to 5.0 ⁇ 10 5 cells / cm 2 , and even more preferably 0.5 ⁇ 10 5 cells / cm 2 to 3.0 ⁇ . It is 10 5 cells / cm 2 . It is preferable that the cell seeding density is in the above range because cell proliferation and differentiation can be performed more efficiently as compared with the case outside the above range.
- the medium used for seeding is not particularly limited as long as it is a medium in which cells and the like can survive, and may be appropriately selected according to the cells and the like to be used.
- the medium used for sowing may be the medium used in the step (B) described later.
- the medium used for seeding is, for example, an arbitrary cell culture basic medium, a differentiation medium, a medium for primary culture, or the like.
- Escential8 StemFit Medium, ReproFF2 Medium, Stem-PartnerSF, Eagle Small Essential Medium (EMEM), Darveco Kai Eagle Medium (DMEM), ⁇ -MEM, Grassgo MEM (GMEM), IMDM, RPMI1640, Ham F-12, Examples thereof include MCDB medium, Williams medium E, and a mixed medium thereof. Further, a medium containing serum, various growth factors, differentiation-inducing factors, antibiotics, hormones, amino acids, sugars, salts, minerals, metals, vitamins and the like may be used.
- the amount of the medium used for sowing is not particularly limited, but the height of the medium is preferably 3 to 30 mm, more preferably 3 to 25 mm, still more preferably 4 to 20 mm in the state of being added to the culture vessel.
- the culture temperature is not particularly limited, but is usually about 25 to 40 ° C.
- Step (B) The method of culturing cells or the like in contact with the culture surface to form spheroids is not particularly limited as long as oxygen, nutrients, etc. can be supplied to the cells or the like in contact with the culture surface and the cells or the like can be cultured to form spheroids.
- oxygen is supplied to a culture incubator containing a culture device to which a medium is added, and oxygen is supplied to cells or the like via a culture member to maintain the temperature at 37 ° C. for a certain period of time.
- the medium used for cell culture may be appropriately selected according to the cells.
- the type of medium is not particularly limited, but for example, any cell culture basic medium, differentiation medium, primary culture-dedicated medium, or the like can be used. Specifically, Essential8, Eagle's Small Essential Medium (EMEM), Dalveco Kai Eagle's Medium (DMEM), ⁇ -MEM, Glasgow MEM (GMEM), IMDM, RPMI1640, Ham F-12, MCDB Medium, Williams Medium E, Hepatocyte Examples thereof include the medium and a mixed medium thereof, but the medium is not limited to these, and any medium containing components necessary for cell proliferation and differentiation can be used.
- a medium containing serum, various growth factors, differentiation-inducing factors, antibiotics, hormones, amino acids, sugars, salts and the like may be used.
- the culture temperature is not particularly limited, but is usually about 25 to 40 ° C.
- the amount of the medium is not particularly limited, but the height of the medium is preferably 3 to 30 mm, more preferably 3 to 25 mm, still more preferably 4 to 20 mm.
- the culture period may be appropriately selected according to the type, size, degree of differentiation, etc. of the cells and the spheroids to be formed.
- the culture period is preferably 7 to 30 days, more preferably 10 to 25 days, and preferably 11 to 20 days.
- the method for culturing cells or the like of the present invention may further include a step (C) for inducing differentiation of the cells or the like.
- the method for inducing the differentiation of the cells or the like is not particularly limited, and the differentiation can be induced into the desired differentiated cells according to a known protocol, and a commercially available differentiation-inducing medium or a differentiation kit may be used.
- the conditions for inducing differentiation are not particularly limited and can be appropriately set according to the cell type used, the target differentiated cell type, and the like.
- differentiation can be induced by adding a predetermined cytokine, growth factor or other compound to a culture solution at a predetermined concentration and culturing.
- the cells or the like are preferably undifferentiated pluripotent stem cells, differentiated cells derived from pluripotent stem cells (initiated differentiation induction and already differentiated).
- undifferentiated pluripotent stem cells including pluripotent stem cells in the process), undifferentiated somatic stem cells, differentiated cells derived from somatic stem cells (including somatic stem cells that have started to induce differentiation and are already in the process of differentiation), more preferably.
- the target differentiated cell is not particularly limited and may be any differentiated cell.
- the target differentiated cells include various precursor cells, for example, fat cells, hepatocytes, renal cells, pancreatic cells, mammary gland cells, endothelial cells, epithelial cells, smooth muscle cells, myoblasts, myocardial cells, and nerve cells. , Glia cell, dendritic cell, cartilage cell, osteoblast, osteotomy cell, bone cell, fibroblast, various blood line cells, retinal cell, corneal-derived cell, gonad-derived cell, various line cell and the like.
- the desired differentiated cell is preferably a cell that forms a spheroid, and more preferably a cell having a high oxygen requirement.
- the target differentiated cells are preferably hepatocytes, nerve cells, myocardial cells, pancreatic ⁇ cells, vascular endothelial cells, adipose cells, adipose-derived stem cells, cartilage cells, mesenchymal stem cells, hair follicle epithelial stem cells, and hair papilla cells. , Skin fibroblasts, skin keratinized cells, osteoblasts, hematopoietic precursor cells and the like, more preferably myocardial cells, nerve cells, hepatocytes, and even more preferably myocardial cells.
- the step (C) is preferably a step of inducing the differentiation of pluripotent stem cells into cardiomyocytes, and more preferably a step of inducing the differentiation of iPS cells into cardiomyocytes.
- the method for inducing the differentiation of pluripotent stem cells into cardiomyocytes is not particularly limited.
- Various methods are known as methods for inducing differentiation of pluripotent stem cells into cardiomyocytes (for example, Burridge et al., Cell Stem Cell. 2012 Jan 6; 10 (1): 16-28; Kattman et al., Cell Stem Cell 2011; 8: 228-240; Zhang et al., Circ Res 2012; 111: 1125-1136; Lian et al., Nat Protoc 2013; 8: 162-175; WO 2016/076368 WO 2013/111875; Minami et al., Cell Rep.
- mesoderm-inducing factors eg, Actibin A, BMP4, bFGF, VEGF, SCF, etc.
- cardiac determinants eg, VEGF, DKK1, Wnt signaling inhibitors (eg, IWR-1, IWP-2)) , IWP-4, etc.
- BMP signal inhibitors eg, NOGGIN, etc.
- TGF ⁇ / actibine / NODAL signal inhibitors eg, SB431542, etc.
- retinoic acid signal inhibitors eg, VEGF, bFGF, etc.
- cardiac differentiation factors eg, VEGF, bFGF, etc.
- DKK1, etc. can be sequentially acted on to increase the induction efficiency.
- the method for inducing the differentiation of iPS cells into cardiomyocytes is not particularly limited, but for example, a known protein-free myocardial differentiation induction (PFCD) method can be used (see International Publication No. 2015/182765). Since the protein-free myocardial differentiation induction (PFCD) method can achieve high myocardial differentiation efficiency, the step (C) induces the differentiation of iPS cells into cardiomyocytes by the protein-free myocardial differentiation induction (PFCD) method. It is preferable that the process is to be performed.
- PFCD protein-free myocardial differentiation induction
- the step (C) may be performed after the step (A) and before the step (B), at the same time as the step (B), or as a part of the period during which the step (B) is performed. You may go only to. Since the differentiation of pluripotent stem cells can be induced more efficiently, it is preferable that the step (C) is performed at the same time as the step (B).
- the differentiation induction period in the step (C) can be appropriately set according to the cell type used, the target differentiated cell type, the degree of differentiation, the differentiation induction method, and the like.
- the differentiation induction period is preferably 7 to 30 days, more preferably 10 to 25 days, still more preferably 11 to 20 days.
- the method for culturing cells and the like of the present invention is preferably a method for culturing iPS cells or differentiated cells derived from iPS cells, and more preferably a method for culturing cardiomyocytes derived from iPS cells.
- the method for culturing cells and the like of the present invention preferably increases myocardial purity.
- the increase is pluripotent under experimental conditions in which a polystyrene culture member or device is used instead of the culture member or the culture device, and other conditions are the same as the method for culturing cells and the like of the present invention. It means that the myocardial purity is higher than that of the comparison target, using the myocardial purity when the sex stem cells are differentiated into myocardial cells as a comparative control. It is preferable that the myocardial purity is 1.3 times or more higher than that of the comparison target, it is more preferable that the myocardial purity is 2 times or more, and it is further preferable that the myocardial purity is 3 times or more higher.
- the myocardial purity is the ratio (%) of the number of myocardial cells differentiated from pluripotent stem cells to the total number of differentiated cells derived from pluripotent stem cells.
- the method for measuring the myocardial purity is not particularly limited, and for example, after a predetermined period of differentiation induction has elapsed, the total number of cells and the number of cells expressing the cardiomyocyte marker can be measured and the ratio can be calculated.
- the cells form a spheroid the spheroid can be single-celled by a known method, and the total number of cells constituting the spheroid can be taken as the total number of cells. For example, a hemocytometer, FACS, or the like can be used for measuring the number of cells.
- the cardiomyocyte marker is not particularly limited, and for example, myocardial troponin C (cTnC), myocardial troponin I (cTnI), myocardial troponin T (cTnT), myosin light chain, ⁇ Actinin, NKX2.5, KCNQ1, HERG1b, Cav1.2, Nav1.5 and the like can be mentioned.
- the cardiomyocyte marker is preferably myocardial troponin T (cTnT).
- the number of cells expressing the cardiomyocyte marker can be measured by FACS, for example, using an antibody against the cardiomyocyte marker.
- the myocardial purity can preferably be calculated by the number of cTnT-positive cells / the total number of cells constituting the spheroid ⁇ 100.
- the method for culturing cells and the like of the present invention increases the expression of the MYL2 (Myosin regulatory light chain 2) gene in cardiomyocytes.
- the increase means that a polystyrene culture member or a culture device is used instead of the culture member or the culture device, and the other conditions are the same as the method for culturing cells and the like of the present invention.
- Using the expression level of the MYL2 gene in the myocardial cells when differentiated into the myocardial cells of the sex stem cells as a comparative control it means that the expression level of the MYL2 gene is higher than that of the comparison target.
- the expression level of the MYL2 gene is twice or more higher than that of the comparison target, and it is more preferable that the expression level of the MYL2 gene is three times or more higher than that of the comparison target.
- the expression level of the MYL2 gene can be measured by a known method, and examples thereof include a quantitative RT-PCR method.
- the method for culturing cells and the like of the present invention preferably increases the number of heartbeats of cardiomyocytes.
- the increase means that a polystyrene culture member or a culture device is used instead of the culture member or the culture device, and the other conditions are the same as the method for culturing cells and the like of the present invention.
- the pulsatile number of cardiomyocytes is twice or more higher than that of the comparison target, and it is more preferable that the pulsatile number of cardiomyocytes is three times or more higher than that of the comparison target.
- the number of beats of cardiomyocytes can be measured by a known method. For example, a moving image of cardiomyocytes can be taken and the BPM (number of beats per minute) of any cardiomyocyte can be measured.
- the spheroid of the present invention is formed by the above culture method.
- the spheroid of the present invention is characterized in that it tends to have high uniformity in size and shape because oxygen is supplied to the inside of cells during culturing. Further, since the cells contained in the spheroid of the present invention have normal functions and their cell purity is high, the reliability of the data when the spheroid is used for various tests is high, and the reproducibility is also high. It tends to be expensive.
- the spheroid of the present invention can be suitably used as a cell source for cell function evaluation, drug screening, regenerative medicine and cell therapy.
- test piece is cut out from the film of the production example or the culture vessel of the comparative example in a size of 100 mm ⁇ 10 mm in length ⁇ width, and protrudes horizontally from the horizontal upper surface of the test table by 50 mm with respect to the vertical dimension of the test piece.
- the test piece was fixed to the test table in the state of being fixed, and 3 minutes after the fixing, the distance at which the tip of the test piece protruding from the test table hung vertically downward from the horizontal plane including the upper surface of the test table was measured.
- the room temperature was 23 ° C. from the fixing to the measurement. The results are shown in Table 1.
- the water contact angle was measured according to Japanese Industrial Standards JIS-R3257 (wetting property test method for the surface of the substrate glass). Under constant temperature and humidity conditions of 25 ⁇ 5 ° C and 50 ⁇ 10%, water droplets with a volume of 4 ⁇ L or less, which can be regarded as spherical in shape, are dropped on the surface of the measurement sample, and water droplets are formed on the surface of the measurement sample by the static drip method. The angle of the contact interface between the measurement sample and the water droplet was measured within 1 minute immediately after the contact.
- the oxygen permeability coefficient of the measurement sample was measured in an environment of a temperature of 23 ° C. and a humidity of 0% using a differential pressure type gas permeability measuring device MT-C3 manufactured by Toyo Seiki Seisakusho.
- the diameter of the measuring part was 70 mm (transmission area was 38.46 cm 2 ). Since it was expected that the oxygen permeability coefficient would be large, an aluminum mask was applied to the sample in advance to set the actual permeation area to 5.0 cm 2 .
- the measured oxygen permeability coefficient [cm 3 x mm / (m 2 x 24 h x atm)] is divided by the film (culture member) thickness ( ⁇ m) to obtain oxygen permeability [cm 3 / (m 2 x). 24h ⁇ atm)] was calculated.
- Example 1 Induction of differentiation of iPS cells into cardiomyocytes Using the culture vessel prepared in Production Example 2, differentiation of iPS cells into cardiomyocytes was induced by the method described later to form spheroids. The medium was used so that the height of the medium was 5 mm (medium volume: 1 mL).
- Example 2 Culturing was carried out in the same manner as in Example 1 except that the amount of medium was increased from that of Example 1 and the height of the medium was set to 10 mm (medium amount: 1.8 mL).
- Example 1 Example 1 and Example 1 except that an ultra-low adhesive surface PS culture container (Corning Inc., Costar TM 3473, 1-well culture surface inner diameter 15 mm, 24-well plate) having a culture surface thickness of 1000 ⁇ m was used. The cells were cultured in the same manner.
- the ultra-low adhesive surface PS culture container is a commercially available PS culture container (water contact angle 61 °) that has been hydrophilized. Table 1 shows the results of measuring the water contact angle.
- Comparative Example 2 Culturing was carried out in the same manner as in Comparative Example 1 except that the amount of the medium was increased as compared with Comparative Example 1 and the height of the medium was set to 10 mm.
- IPS cell culture ⁇ Preparation of medium and reagents> Human-derived iPS cells (provided by iPS Cell Research Institute) cryopreserved in liquid nitrogen were used.
- the reagents used are as follows. ⁇ Essential 8 (Product No. A151001, Gibco) -IMatrix-511 silk (Product No. 387-10131, Nippi) -CultureSure TM Y-27632 (Product No. 034-24024, Fuji Film Wako Pure Chemical Industries, Ltd.) -0.5 mol / L-EDTA solution (pH 8.0) (Product No. 06894-85, Nacalai Tesque) ⁇ PBS (-) (Product No.
- the medium and reagents were prepared as follows.
- -IPS cell medium Essential 8 was used after being brought to room temperature at the time of use.
- CultureSure TM Y-27632 was added so as to be 3 ⁇ M and used.
- -Medium for inducing myocardial differentiation At the time of use, the small molecule compound group A or the small molecule compound group B was mixed with the myocardial differentiation inducing medium and heated to 37 ° C. before use.
- -Exfoliation solution 0.5 mol / L-EDTA solution (pH 8.0) was adjusted to 0.5 mM with PBS (-). At the time of use, it was used after heating to 37 ° C.
- -Y-27632 solution Adjusted to 10 mM with PBS (-).
- -Single solution 2.5% Trypsin was adjusted to 0.25% with PBS (-). At the time of use, it was used after heating to 37 ° C.
- -Saponin solution Saponin from Soybeans was adjusted to a 0.1% solution with PBS (-).
- -Preservation conditions Y-27632 solution, single solution, and other reagents necessary for cardiomyocyte culture were stored frozen, and the medium and exfoliation solution were stored refrigerated.
- ⁇ Culture schedule> Cell culture was performed according to the following schedule. For iPS cells, cells that had been passaged 5 times from wakefulness were subjected to differentiation induction. Sampling was performed on the 12th day when cardiomyocyte pulsation was confirmed overall and on the 19th day when the cells were more matured.
- Day-1 Reagent preparation and preparation
- Day0 iPS cell dormancy
- Day3 iPS cell passage (day3, 6, 10, 15, 19 total 5 passages)
- Day23 Start of induction of myocardial differentiation of iPS cells (day 0)
- Day 45 Sampling and single cellization on day 12 of myocardial differentiation induction (FACS, gene expression analysis)
- Day 39 Sampling and single cellization on day 19 of induction of myocardial differentiation (FACS, gene expression analysis)
- ⁇ IPS cell culture method Thawing of iPS cells 1) Before thawing of iPS cells, 10 mL of medium was placed in a tube and heated in a 37 ° C. water bath. 2) The frozen iPS cell tube was semi-dissolved in a 37 ° C. water bath and slowly transferred to a tube containing 10 mL of warmed medium in a clean bench. 3) After centrifugation at 100 ⁇ g at room temperature for 3 minutes, the supernatant was removed. 4) 10 mL of new medium was added and mixed lightly, 0.13 ⁇ g / cm 2 of iMatrix-511 silk was added to the cell suspension, seeded at 10 cm dish, and cultured at 37 ° C. in a 5% CO 2 incubator.
- iPS cell passage 1 The state of the cells was observed with a phase-contrast microscope, and the split ratio of the passage was determined between 1: 12-1: 20. 2) The culture medium supernatant was collected in a tube. After washing with PBS (-), a stripping solution was added, and the mixture was reacted in a 5% CO 2 incubator at 37 ° C. for about 5 minutes. 3) After the reaction, the dish was tilted to peel off the cells, and the collected supernatant was used to collect the cells in a tube. 4) After centrifugation at 100 ⁇ g at room temperature for 3 minutes, the supernatant was removed.
- ⁇ Method for inducing myocardial differentiation> The outline of the experiment schedule is shown in FIG.
- the differentiation of iPS cells into cardiomyocytes was induced by the protein-free cardiomyocyte differentiation induction (PFCD) method.
- Day 0 Approximately 50% confluent iPS cells were stripped with a stripping solution and then centrifuged at 100 xg at room temperature for 3 minutes. After removing the supernatant, the cells were suspended in fresh medium, seeded in untreated 55 cm 2 dish, and allowed to stand in a 5% CO 2 incubator at 37 ° C. for 4 hours. Then, the cells were collected in a tube and replaced with a myocardial differentiation-inducing medium supplemented with the small molecule compound group A.
- PFCD protein-free cardiomyocyte differentiation induction
- ⁇ Single cell formation of cell mass (sampling on days 12 and 19 of differentiation induction)> 1) The cell mass (which is considered to be a myocardial mass) was collected in a tube, and when the cell mass spontaneously settled, the supernatant was removed. 2) 1 mL of the unifying solution was added, and the mixture was heated in a water bath at 37 ° C. for about 30 minutes and stirred until the cell mass became a single cell. 3) The reaction was stopped by diluting with 3 times the amount of PBS ( ⁇ ) 3 mL. 4) Cell counting of the cell suspension was performed and used for FACS or RNA extraction described later.
- RNA extraction miRNeasy Mini Kit (Product No. 217004, manufactured by Qiagen)
- cDNA synthesis RiverTra Ace (R)
- qPCR RT Master Mix with gDNA Remover Product No. FSQ-301, manufactured by TOYOBO
- qPCR reaction PowerUp SYBR Green Master Mix (Product No. A25776, manufactured by Thermo Fisher)
- QuantStudio 6 Flex Real-time PCR system manufactured by Thermo Fisher
- Nanophotometer Spectrophotometer C40 manufactured by Wakenbee Tech Co., Ltd.
- RNA extraction Induction of differentiation into cardiomyocytes After removing the culture supernatants on the 12th and 19th days, 0.5 mL of QIAZOL (manufactured by Qiagen) was added, suspended to lyse the cells, and the lysate. was collected in a 1.5 ml tube. After that, RNA was extracted according to the protocol attached to miRNeasy Mini Kit, and the RNA concentration was measured with Nanophotometer C40.
- RNA extracted from cells on the 12th and 19th days of differentiation induction the gene expression level was analyzed by QuantStudio 6 Flex Real-time PCR system.
- the sequences of the primers used are shown in Table 2, and the PCR conditions are shown in Table 3.
- the gene expression level is shown as a relative value when the gene expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is 1.
- GPDH glyceraldehyde-3-phosphate dehydrogenase
- Examples 1 and 2 had a higher cell proliferation rate because the oxygen permeability of the bottom of the culture was higher than that of Comparative Examples 1 and 2, especially when the medium height was 10 mm. .. A similar tendency was seen on the 19th day.
- Examples 1 and 2 had higher myocardial purity than Comparative Examples 1 and 2 on the 12th and 19th days of differentiation induction.
- the expression of the myocardial-specific genes Troponin, MYL2, and MYL7 was compared, the expression levels of all the genes were higher in Examples 1 and 2 than in Comparative Examples 1 and 2, especially when the medium height was 10 mm. There were many.
- Example 1 and 2 the number of beats was higher in Comparative Examples 1 and 2 on the 19th day of differentiation induction, and the number of beats was higher in the liquid depth of 10 mm than in 5 mm. Further, as a result of morphological observation, it was clarified that in Examples 1 and 2, a plurality of spheroids having a uniform size and shape were formed as compared with Comparative Examples 1 and 2. Further, in Examples 1 and 2, it was clarified that iPS cells differentiated into cardiomyocytes more efficiently than in Comparative Examples 1 and 2.
- Example 3 Culture of human osteosarcoma-derived cancer cells (HOF-143B) Using the culture vessel prepared in Production Example 2, human osteosarcoma-derived cancer cells (HOF-143B) were cultured by the method described later. Spheroids were formed.
- Example 3 In the same manner as in Example 3 except that a commercially available TCPS culture vessel having a culture surface thickness of 1000 ⁇ m (inner diameter of the culture surface is 16 mm, 24-well plate, manufactured by Corning Inc., made of polystyrene (PS)) was used. It was cultured.
- TCPS culture vessel having a culture surface thickness of 1000 ⁇ m (inner diameter of the culture surface is 16 mm, 24-well plate, manufactured by Corning Inc., made of polystyrene (PS) was used. It was cultured.
- PS polystyrene
- Example 4 A commercially available PDMS (polydimethylsiloxane) culture container having a culture member thickness of 350 ⁇ m as a high oxygen permeation container (culture surface inner diameter is 15 mm, 24-well plate, product name G-platate, manufactured by VECELL, model number V24WGPB). was cultured in the same manner as in Example 3 except that.
- PDMS polydimethylsiloxane
- ⁇ Cell culture> A cell suspension containing cancer cells derived from human osteosarcoma was seeded on the culture surface with a micropipette, brought into an incubator, and the culture was started at 37 ° C. and 5% CO 2 . The culture was carried out for 7 days. Medium exchange was performed on the 3rd and 6th days after cell seeding. The medium was exchanged by allowing the culture vessel to stand, removing the supernatant with the spheroids sufficiently settled, and adding the removed amount of medium.
- the culture member of the present invention was used, cell spheroids having normal functions were formed. Furthermore, it was clarified that iPS cells efficiently differentiate into cardiomyocytes by using the culture member of the present invention. That is, the culture member of the present invention easily forms spheroids and easily differentiates pluripotent stem cells. Therefore, the culture member of the present invention can be suitably used for drug discovery screening, diagnosis, and regenerative medicine.
Abstract
Description
〔1〕 細胞、組織、または器官をその培養面上で培養する培養部材であり、前記培養部材は4-メチル-1-ペンテン重合体(X)を含み、前記培養面の水接触角が100°より大きく160°以下であり、温度23℃、湿度0%の時の酸素透過度が4500~90000cm3/(m2×24h×atm)である培養部材。
〔2〕 前記4-メチル-1-ペンテン重合体(X)が、4-メチル-1-ペンテンとエチレンおよび炭素数3~20のα―オレフィン(4-メチル-1-ペンテンを除く)から選ばれる少なくとも1種の共重合体(x1)である、〔1〕に記載の培養部材。
〔3〕 前記培養面が、凹凸構造の形成加工を施されていない、〔1〕または〔2〕に記載の培養部材。
〔4〕 スフェロイド形成用である、〔1〕~〔3〕のいずれかに記載の培養部材。
〔5〕 前記細胞、組織、または器官が、iPS細胞由来の分化細胞を含む、〔1〕~〔4〕のいずれかに記載の培養部材。
〔6〕 前記細胞、組織、または器官が、心筋細胞を含む、〔1〕~〔5〕のいずれかに記載の培養部材。
〔7〕 前記培養部材の形状がフィルム状またはシート状である、〔1〕~〔6〕のいずれかに記載の培養部材。
〔8〕 少なくとも培養面が、〔1〕~〔7〕のいずれかに記載の培養部材で形成された、培養器具。
〔9〕 〔1〕~〔7〕のいずれかに記載の培養部材または〔8〕に記載の培養器具の培養面に、細胞、組織または器官を接触させる工程(A);および
前記培養面に接触した細胞、組織または器官を培養してスフェロイドを形成させる工程(B);を含む細胞、組織または器官の培養方法。
〔10〕 さらに、前記細胞等の分化を誘導する工程(C)を含み、工程(C)が、プロテインフリー心筋分化誘導(PFCD)法により、iPS細胞の心筋細胞への分化を誘導する工程である、〔9〕に記載の細胞、組織または器官の培養方法。
〔11〕 心筋純度を増加させる、〔9〕または〔10〕に記載の細胞、組織または器官の培養方法。
〔12〕 〔9〕~〔11〕のいずれかに記載の培養方法により形成されたスフェロイド。
本発明に係る培養部材は、その培養面で細胞、組織または器官(以下、細胞等ともいう)を培養する部材であり、前記培養部材は4-メチル-1-ペンテン重合体(X)を含み、前記培養面の水接触角が100°より大きく160°以下であり、温度23℃、湿度0%の時の酸素透過度が4500~90000cm3/(m2×24h×atm)であることに特徴がある。
ここで、培養部材とは、細胞等を培養するために用いられる培養器具の少なくとも一部を構成する部材を意味する。培養部材が前記培養器具の一部である場合、少なくとも細胞等を培養する培養面が、本発明の培養部材により構成される。ここで培養面とは、細胞等を培養する際に、培地が形成される面、細胞等が播種される面、または培地が形成されかつ細胞等が播種される面を意味する。すなわち、培養面とは、培地形成予定面および細胞等播種予定面を包含する概念である。
本発明の培養部材は、その表面を加工しなくても、細胞が接着しにくいため、スフェロイドを形成させることができる。したがって、本発明の培養部材は、その表面を加工されていないことが好ましく、凹凸構造の形成加工を施されていないことがより好ましい。
本発明においては、4-メチル-1-ペンテン単独重合体、および4-メチル-1-ペンテンと他のモノマーとの共重合体を総称して「4-メチル-1-ペンテン重合体(X)」と称する。
4-メチル-1-ペンテン重合体の一例である、4-メチル-1-ペンテンと、他のモノマーとの共重合体としては、ランダム共重合体、交互共重合体、ブロック共重合体、グラフト共重合体のいずれであってもよい。4-メチル-1-ペンテンと、他のモノマーとの共重合体としては、4-メチル-1-ペンテンと、エチレンおよび炭素数3~20のα-オレフィン(4-メチル-1-ペンテンを除く)から選ばれる少なくとも1種のオレフィンとの共重合体が、強度が高く、部材として用いても破れにくく割れにくく、撓みも少ないため好ましい。
また、4-メチル-1-ペンテン重合体が、4-メチル-1-ペンテンと、エチレンおよび炭素数3~20のα-オレフィン(4-メチル-1-ペンテンを除く)から選ばれる少なくとも1種のオレフィンとの共重合体である場合は、その共重合体におけるエチレンおよび炭素数3~20のα-オレフィン(4-メチル-1-ペンテンを除く)から選ばれる少なくとも1種のオレフィンから導かれる構成単位の含有量は、好ましくは0~40モル%、より好ましくは2~20モル%である。なお、これら構成単位の含有量は、4-メチル-1-ペンテン重合体中の全繰返し構成単位量を100モル%とする。構成単位の含有量が上記範囲内にあると、加工性に優れ均質な培養面が得られ、またフィルムの靭性と強度のバランスが良いため、撓みも少なくなる。
前記4-メチル-1-ペンテン重合体を製造する方法は、4-メチル-1-ペンテン、オレフィン、その他のモノマーを重合させられれば、いずれの方法であってもよい。また、分子量や分子量分布を制御するために連鎖移動剤、例えば水素を共存させてもよい。製造に用いる機器も制限されない。重合法は公知の方法でもよく、気相法、スラリー法、溶液法、バルク法であってもよい。好ましくはスラリー法、溶液法である。また、重合法は単段重合法、または二段等の多段重合法で、分子量の異なる複数の重合体を重合系中にブレンドする方法であってもよい。単段、多段重合法の何れであっても、連鎖移動剤として水素を用いる場合には、一括投入しても、分割投入、例えば重合初期、中期、終期に投入してもよい。重合は常温で行ってもよく、必要に応じて加温してもよいが、重合の効率の観点から、20℃~80℃で行うことが好ましく、40℃~60℃で行うことが特に好ましい。製造に用いる触媒も制限されないが、重合の効率の観点から、例えば国際公開公報2006/054613に記載される固体状チタン触媒成分(I)や、国際公開公報2014/050817に記載される遷移金属化合物(A)を含有するオレフィン重合用触媒(メタロセン触媒)を用いることが好ましい。
本発明の培養部材は、その培養面の水接触角が100°より大きく160°以下である。前記水接触角は、好ましくは100°より大きく150°以下であり、より好ましくは100°より大きく130°以下であり、さらに好ましくは105°より大きく130°以下である。培養部材の培養面の水接触角が100°以下であると、細胞等が培養部材と接着してしまい、スフェロイドを形成しにくい。また、培養部材の培養面の水接触角が160°より大きいと、培養面と培地の接触が不十分となり、培地内への酸素供給効率が低下してしまう。
本発明の培養部材の温度23℃、湿度0%の時の酸素透過度は、4500~90000cm3/(m2×24h×atm)であり、好ましくは4500~67500cm3/(m2×24h×atm)であり、より好ましくは4500~47000cm3/(m2×24h×atm)であり、さらに好ましくは4500~45000cm3/(m2×24h×atm)である。
本明細書において、細胞、組織、または器官は、単に「細胞等」とも称する。細胞等の由来は、特に限定されず、動物、植物、昆虫、菌、原生生物、細菌などあらゆる生物であってよいが、動物、または植物が好ましく、動物がさらに好ましく、特に哺乳動物が好ましい。本発明の培養部材は、細胞等の接着を避けて培養することができ、酸素透過性にも優れるので、細胞等は非接着性のものであることが好ましい。
動物細胞としては、正常細胞、がん細胞、およびハイブリドーマ等の融合細胞等が使用でき、遺伝子導入等の人工的処理がされた細胞であってもよい。動物細胞は、初代培養細胞あるいは株化継代された細胞のいずれであってもよい。動物細胞は、浮遊性細胞であってもよく、接着性細胞であってもよい。動物細胞としては、例えば、未分化の多能性幹細胞、多能性幹細胞由来の分化細胞(分化誘導を開始し、既に分化の過程にある多能性幹細胞を含む)、未分化の体性幹細胞、体性幹細胞由来の分化細胞(分化誘導を開始し、既に分化の過程にある体性幹細胞を含む)、および動物の組織に由来する分化細胞が挙げられる。
また、ヒトES細胞株は、例えばWA01(H1)およびWA09(H9)は、WiCell Reserch Instituteから、KhES-1、KhES-2およびKhES-3は、京都大学再生医科学研究所(京都、日本)から入手可能である。
培地の量は特に制限されないが、培地の高さは好ましくは3~30mm、より好ましくは3~25mm、さらに好ましくは4~20mmである。
本発明において、培養器具とは、細胞等の培養に用いる器具全てを意味する。前記培養器具は、少なくともその一部が前記培養部材から構成される。前記培養器具は、その全部が前記培養部材から構成されてもよいし、その一部のみが前記培養部材から構成されてもよい。前記培養器具の一部のみが前記培養部材から構成される場合、少なくも細胞等を培養する培養面が、本発明の培養部材により構成される。
培養器具の培養面を天然高分子材料、合成高分子材料、または無機材料でコーティングすると、細胞等の増殖性がより優れるが、細胞等が培養面に接着しやすくなる。
培養面へのコーティングの有無は、細胞等の種類に応じて決定することができるが、通常、コーティングしない方が好ましい。
本発明の細胞等の培養方法は、細胞、組織、または器官をその培養面上で培養する培養部材であり、前記培養部材は4-メチル-1-ペンテン重合体(X)を含み、前記培養面の水接触角が100°より大きく160°以下であり、温度23℃、湿度0%の時の酸素透過度が4500~90000cm3/(m2×24h×atm)である培養部材、または少なくとも培養面が、前記培養部材で形成された培養器具の培養面に、細胞、組織または器官を接触させる工程(A);および前記培養面に接触した細胞、組織または器官を培養してスフェロイドを形成させる工程(B);を含む細胞、組織または器官の培養方法である。
培養部材または培養器具の培養面に、細胞等を接触させる方法は、培養部材または培養器具の培養面に細胞等を接触させることができれば特に制限されず、例えば、培養部材または培養器具の培養面に細胞等を播種することが挙げられる。より具体的には、例えば、培地に懸濁した細胞等をピペット等で培養容器内に添加し、必要に応じて該培養容器を揺動させて培養容器内に細胞を均等に散らした後、インキュベーター内で静置する。
細胞播種密度が上記の範囲であると、上記範囲外の場合と比べて、細胞の増殖および分化がより効率よく行えるため好ましい。
細胞等が未分化の多能性幹細胞、または多能性幹細胞由来の分化細胞である場合、播種に用いる培地は、例えば、任意の細胞培養基本培地や分化培地、初代培養専用培地等、具体的には、Essential8、StemFit培地、ReproFF2培地、Stem-PartnerSF、イーグル細小必須培地(EMEM)、ダルベッコ改イーグル培地(DMEM)、α-MEM、グラスゴーMEM(GMEM)、IMDM、RPMI1640、ハムF-12、MCDB培地、ウィリアムス培地Eおよびこれらの混合培地等が挙げられる。さらに、血清、各種成長因子、分化誘導因子、抗生物質、ホルモン、アミノ酸、糖、塩類、ミネラル、金属、ビタミン等を添加した培地を使用してもよい。
培養温度も特に制限されないが、通常は25~40℃程度で行う。
培養面に接触した細胞等を培養してスフェロイドを形成させる方法は、培養面に接触した細胞等に酸素、栄養等を供給して、細胞等を培養してスフェロイドを形成できれば特に制限されず、例えば、培地を添加した培養器具を入れた培養インキュベーターに酸素を供給し、培養部材を介して細胞等に酸素を供給して、一定期間37℃に保つことが挙げられる。
培地の量は特に制限されないが、培地の高さは好ましくは3~30mm、より好ましくは3~25mm、さらに好ましくは4~20mmである。
本発明の細胞等の培養方法は、さらに、前記細胞等の分化を誘導する工程(C)を含んでもよい。
前記細胞等の分化を誘導する方法は特に制限されず、公知のプロトコルに従って所望の目的とする分化細胞への分化誘導を行えばよく、市販の分化誘導培地や分化キットを用いてもよい。
本発明の細胞等の培養方法は、好ましくはiPS細胞またはiPS細胞由来の分化細胞の培養方法であり、さらに好ましくはiPS細胞由来の心筋細胞の培養方法である。
前記増加とは、前記培養部材または前記培養器具の代わりに、ポリスチレン製の培養部材または培養器具を用い、それ以外の条件は本発明の細胞等の培養方法と同じである実験条件下において多能性幹細胞を心筋細胞へ分化させた際の心筋純度を比較対照として、該比較対象よりも心筋純度が高いことを言う。前記比較対象よりも1.3倍以上心筋純度が高いことが好ましく、2倍以上心筋純度が高いことがより好ましく、3倍以上心筋純度が高いことがさらに好ましい。
細胞数の計測には、例えば、血球計算板、FACS等を用いることができる。
心筋細胞マーカーを発現する細胞数の測定は、例えば、心筋細胞マーカーに対する抗体を用いてFACSで行うことができる。
前記心筋純度は、好ましくは、cTnT陽性細胞数/スフェロイドを構成する全細胞数×100で算出することができる。
前記増加とは、前記培養部材または前記培養器具の代わりに、ポリスチレン製の培養部材または培養器具を用い、それ以外の条件は本発明の細胞等の培養方法と同じである実験条件下において多能性幹細胞の心筋細胞へ分化させた際の心筋細胞のMYL2遺伝子の発現量を比較対照として、該比較対象よりもMYL2遺伝子の発現量が高いことを言う。前記比較対象よりも2倍以上MYL2遺伝子の発現量が高いことが好ましく、3倍以上MYL2遺伝子の発現量が高いことがより好ましい。
MYL2遺伝子の発現量は、公知の方法で測定することができ、例えば定量RT-PCR法が挙げられる。
前記増加とは、前記培養部材または前記培養器具の代わりに、ポリスチレン製の培養部材または培養器具を用い、それ以外の条件は本発明の細胞等の培養方法と同じである実験条件下において多能性幹細胞の心筋細胞へ分化させた際の心筋細胞の拍動数を比較対照として、該比較対象よりも拍動数が高いことを言う。前記比較対象よりも2倍以上心筋細胞の拍動数が高いことが好ましく、3倍以上心筋細胞の拍動数が高いことがより好ましい。
心筋細胞の拍動数は、公知の方法で測定することができ、例えば、心筋細胞の動画を撮影し、任意の心筋細胞のBPM(1分間における拍動数)を測定することができる。
上記培養方法によって、本発明のスフェロイドが形成される。
本発明のスフェロイドは、培養時に細胞内部にまで酸素供給が行われるため、大きさおよび形状の均一性が高い傾向にあることが特徴である。また、本発明のスフェロイドに含まれる細胞は、正常な機能を保有しており、その細胞純度も高いので、スフェロイドを各種検査に用いた場合のデータの信頼性が高くなり、また、再現性も高くなりやすい。
本発明のスフェロイドは、細胞の機能評価および薬剤のスクリーニング、さらに、再生医療や細胞治療の細胞ソースとして好適に用いることができる。
実施例に用いた4-メチル-1-ペンテン重合体の重量平均分子量Mw、および、分子量分布(Mw/Mn)をゲルパーミュエーションクロマトグラフィー(GPC)により測定した。
具体的には、下記の条件で、オルトジクロロベンゼンに溶解したポリマーの重量平均分子量(Mw)および数平均分子量(Mn)を、標準ポリスチレンによって分子量を較正して測定した。
・装置:ゲル浸透クロマトグラフ HLC-8321 GPC/HT型(東ソー社製)
・データ解析ソフト:Empower3(Waters社製)
・検出器:示差屈折計
・直列連結カラム:TSKgel GMH6-HT(2本)、および、TSKgel GMH6-HTL(2本)
・カラム温度:140℃
・流量:1.0ml/分
・試料濃度:1.5mg/ml
製造例のフィルムまたは比較例の培養容器から、縦×横が100mm×10mmのサイズで試験片を切り出して、該試験片の縦寸法に対して50mmだけ試験台の水平な上面から水平方向へはみ出した状態で試験台に固定し、固定から3分後に、試験台からはみ出した試験片の先端が試験台の上面を含む水平面から鉛直下方へ垂れ下がった距離を測定した。前記固定から測定までは室温23℃であった。結果を表1に示す。
分化誘導19日目にインキュベーターから培養容器を取り出して、容器底面を横方向から覗き込み、培養環境におけるフィルムの垂れ下がりの有無を観察した。容器作製時と比べて変化が無く、フィルムの垂れ下がりが見られない場合を「撓みなし」とし、培養容器作製時と比べて変化があり、フィルムの垂れ下がりが見られる場合を「撓みあり」と評価した。
水接触角の測定は、日本工業規格JIS-R3257(基板ガラス表面のぬれ性試験方法)に準じて行った。25±5℃、50±10%の恒温恒湿条件下で水滴の形状を球形とみなせる4μL以下の容量の水滴を、測定サンプルの表面に滴下し、静滴法により、測定サンプル表面に水滴が接触した直後から1分以内の測定サンプルと水滴の接触界面の角度を測定した。
測定サンプルについて、東洋精機製作所製差圧式ガス透過率測定装置MT-C3を用いて温度23℃、湿度0%の環境下にて酸素透過係数を測定した。測定部径は70mm(透過面積は38.46cm2)とした。酸素透過係数が大きいことが予想されたため、予めサンプルにアルミニウムマスクを施し、実透過面積を5.0cm2とした。
測定した酸素透過係数[cm3×mm/(m2×24h×atm)]の値をフィルム(培養部材)の厚さ(μm)で除して、酸素透過度[cm3/(m2×24h×atm)]を算出した。
4-メチル-1-ペンテン重合体であるTPX(登録商標)(三井化学株式会社製:分子量(Mw)=428000、分子量分布(Mw/Mn)=4.1)を使用し、基材層を押し出すフルフライト型のスクリューを備えたTダイ付き押出機へ投入し、押出し温度を270℃、ロール温度を60℃に設定し、ロール回転速度の条件を変えて押出し成形することで、厚さ50μmのフィルムを得た。得られた前記フィルムについて、水接触角および酸素透過度を測定した。結果を表1に示す。
前記フィルムを8cm×12cmサイズにカットし、ポリスチレン(PSとも称す)製24ウェル容器枠の底面に、医療用粘着剤(スリーエム製)を介して密着させて24ウェルの培養プレートを作製した。その後、耐ガンマ線袋に梱包して10kGyのガンマ線を照射し滅菌した。
製造例2で作製した培養容器を用い、後述する方法によりiPS細胞から心筋細胞への分化を誘導し、スフェロイドを形成させた。培地は培地高さが5mmとなるように用いた(培地量:1mL)。
実施例1よりも培地の量を増やして、培地高さを10mmとした以外は、実施例1と同様にして培養を行った(培地量:1.8mL)。
培養面の厚さが1000μmである超低接着面PS製培養容器(コーニング社製、CostarTM3473、1ウェルの培養面の内径が15mm、24ウェルプレート)を使用した以外は、実施例1と同様な方法で培養した。該超低接着面PS製培養容器は、市販のPS製培養容器(水接触角61°)を親水化処理したものである。水接触角を測定した結果を表1に示す。
比較例1よりも培地の量を増やして、培地高さを10mmとした以外は、比較例1と同様にして培養を行った。
<培地および試薬の調製>
液体窒素中で凍結保存したヒト由来iPS細胞(iPS細胞研究所提供)を用いた。
使用試薬は以下の通りである。
・Essential 8(製品番号A1517001、Gibco)
・iMatrix-511 silk(製品番号387-10131、Nippi)
・CultureSureTMY-27632(製品番号 034-24024、富士フィルム和光純薬)
・0.5mol/L-EDTA溶液(pH8.0)(製品番号06894-85、ナカライテスク)
・PBS(-)(製品番号166-23555、富士フィルム和光純薬)
・2.5%Trypsin(製品番号15090-046、Gibco)
・Trypan blue(製品番号145-0022、Bio-Rad)
・ホルムアルデヒド溶液(製品番号064-00406、富士フィルム和光純薬)
・anti-Troponin T-C(CT3)(製品番号SC-20025、Santacruz)
・anti-Mouse IgG(H+L)Alexa Fluor 647(製品番号A-21236、Thermo Fisher)
・Saponin from Soybeans(製品番号192-08851、富士フィルム和光純薬)
・心筋分化誘導培地(低分子化合物群A、低分子化合物群B):国際公開公報2015/182765号公報段落[0064]および[0065]の記載に従う。
・iPS細胞培地:Essential 8は使用時に室温にしてから使用した。解凍時と継代時に使用する培地はCultureSureTMY-27632を3μMになるように添加し使用した。
・心筋分化誘導培地:使用時に心筋分化誘導培地に低分子化合物群Aまたは低分子化合物群Bを混合し、37℃に加温してから使用した。
・剥離液:0.5mol/L-EDTA溶液(pH8.0)をPBS(-)で0.5mMに調整した。使用時には37℃に加温してから使用した。
・Y-27632溶液:PBS(-)で10mMに調整した。
・シングル化溶液:2.5%TrypsinをPBS(-)で0.25%に調整した。使用時には37℃に加温してから使用した。
・サポニン溶液:Saponin from SoybeansをPBS(-)で0.1%溶液に調整した。
・保存条件:Y-27632溶液、シングル化溶液、その他心筋細胞培養に必要な試薬は冷凍保存し、培地および剥離液は冷蔵保存した。
細胞培養は下記のスケジュールで行った。iPS細胞は起眠から5継代した細胞を分化誘導に供した。サンプリングは心筋細胞の拍動が全体的に確認される12日目と、より成熟化させた19日目で行った。
Day-1:試薬調製および準備
Day0:iPS細胞起眠
Day3~:iPS細胞の継代(day3、6、10、15、19 合計5継代)
Day23:iPS細胞の心筋分化誘導開始(0日目)
Day45:心筋分化誘導12日目のサンプリングおよびシングルセル化(FACS、遺伝子発現解析)
Day39:心筋分化誘導19日目のサンプリングおよびシングルセル化(FACS、遺伝子発現解析)
iPS細胞の解凍
1)iPS細胞の解凍前に、チューブに培地を10mL入れて37℃ウォーターバスで加温した。
2)凍結iPS細胞チューブは37℃ウォーターバスで半溶解状態にし、クリーンベンチ内で加温しておいた培地10mLの入ったチューブにゆっくり移した。
3)100×gで室温、3分間の遠心後、上清を除去した。
4)新しい培地10mLを加えて軽く混和し、0.13μg/cm2のiMatrix-511 silkを細胞懸濁液に添加後、10cm dishに播種し、37℃、5%CO2インキュベーターで培養した。
1)位相差顕微鏡で細胞の状態を観察し、1:12-1:20の間で継代のスプリット比を決めた。
2)培地上清をチューブに回収した。PBS(-)で洗浄後、剥離液を添加し、37℃、5%CO2インキュベーターで約5分間反応させた。
3)反応後、ディッシュを傾けて細胞を剥がし、回収しておいた上清を使って細胞をチューブに回収した。
4)100×gで室温、3分間の遠心後、上清を除去した。
5)新しい培地10mLを加えて軽く混和し、0.13μg/cm2のiMatrix-511 silkを細胞懸濁液に添加後、10cm dishに播種し、37℃、5%CO2インキュベーターで培養した。
実験スケジュールの概略を図1に示す。プロテインフリー心筋分化誘導(PFCD)法により、iPS細胞の心筋細胞への分化を誘導した。
0日目:約50%コンフルエントのiPS細胞を剥離液で剥がした後、100×gで室温、3分間遠心した。上清除去後に新しい培地で懸濁し、未処理の55cm2dishに播種して37℃、5%CO2インキュベーターで4時間静置した。その後、細胞をチューブに回収し、低分子化合物群Aを添加した心筋分化誘導培地に置換した。実施例または比較例の24ウェルプレートに2×105cells/ウェルで細胞を播種し、37℃、5%CO2インキュベーターで培養した。実験はtriplicateで行った。
3日目:培地を低分子化合物群Bの入った心筋分化誘導培地に交換した。
5日目:培地を低分子化合物群Bの入った心筋分化誘導培地に交換した。
7日目以降:3~4日ごとに心筋分化誘導培地で培地交換を行った。なお、分化誘導3日目、7日目の培地交換時にウェルを交換した。
1)細胞塊(心筋塊であると考えられる)をチューブに回収し、細胞塊が自然沈降したら上清を除去した。
2)シングル化溶液を1mL添加し、37℃ウォーターバスで30分前後加温し、細胞塊がシングルセルになるまで撹拌した。
3)3倍量のPBS(-)3mLで希釈し反応を停止した。
4)細胞懸濁液のセルカウントを行い、後述のFACS、またはRNA抽出に用いた。
シングル化した細胞1×106cellsをチューブに移し、300×gで室温にて5分間の遠心後に上清を除去してPBS(-)1mLで再懸濁した。細胞懸濁液にホルムアルデヒド(富士フイルム和光純薬)を終濃度4%となるように加え、室温で5分間静置した。300×gで室温にて3分間遠心し、上清を除去後、サポニン溶液を1mL加えて懸濁し、2本のチューブにそれぞれ0.7mL(サンプル)と0.3mL(ネガティブコントロール)ずつ分注した。再度遠心して上清を除去した後、サンプルには一次抗体としてanti-Troponin T-C(CT3)抗体を1:1000で添加したサポニン溶液0.5mLを添加した。ネガティブコントロールには抗体を添加していないサポニン溶液0.5mLを加えて細胞を懸濁し、4℃で一晩抗体を反応させた。翌日、一次抗体を除去し、二次抗体anti-Mouse IgG(H+L) Alexa Fluor 647を1:500で添加したサポニン溶液0.5mLを加えて遮光し、室温で1時間反応させた。1時間後、二次抗体を添加したサポニン溶液を、PBS(-)0.5mLに置換し、FACS(AccuriTM CS6 Plus(BD社製))で解析を行った。
Troponin(心筋細胞特異的遺伝子)、MYL2(心筋細胞の一つである心室筋特異的遺伝子)、MYL7(心筋細胞の一つである心房筋特異的遺伝子)を解析対象とした。
cDNA合成:ReverTra Ace(R) qPCR RT Master Mix with gDNA Remover(製品番号FSQ-301、TOYOBO社製)
qPCR反応:PowerUp SYBR Green Master Mix(製品番号A25776、Thermo Fisher社製)
QuantStudio 6 Flex Real-time PCR system(Thermo Fisher社製)
Nanophotometer 分光光度計 C40(ワケンビーテック株式会社製)
心筋細胞への分化誘導12日目と19日目の培養上清を除去した後、QIAZOL(キアゲン社製)0.5mLを添加し、懸濁して細胞を溶解し、溶解物を1.5mlチューブに回収した。以降はmiRNeasy Mini Kitに添付のプロトコルに従ってRNAを抽出し、NanophotometerC40でRNA濃度を測定した。
上記で抽出したRNA 1μgを用いて、PowerUp SYBR Green Master Mixに添付のプロトコルに従って逆転写反応を行いcDNAの合成を行った。その後、6ngのcDNAを用いてスタンダード法にてqPCR反応を行った。検量線は10ng/μLの各cDNAサンプルを10μLずつ集め、そこから1/10希釈して5点作製した。
分化誘導12日目と19日目の細胞から抽出したRNAを用い、QuantStudio 6 Flex Real-time PCR systemにて遺伝子発現量の解析を行った。使用したプライマーの配列を表2、PCR条件を表3に示す。遺伝子発現量は、グリセルアルデヒド-3-リン酸デヒドロゲナーゼ(GAPDH)の遺伝子発現量を1とした場合の相対値で示す。結果を表4に示す。
分化誘導12日目と19日目の細胞塊をシングルセル化したあと、トリパンブルー染色(Bio-Rad)による生細胞の計測(TC20全自動セルカウンター、Bio-Radを使用)を行った。
上記で得られた測定値から、細胞生存率(%)(測定時の生細胞数/測定時の全細胞数×100)および、細胞増殖率(%)(測定時の生細胞数/細胞播種(細胞培養開始)時の細胞数×100)を算出した。結果を表4に示す。
分化誘導12日目と19日目の細胞塊をシングルセル化したあと、FACSにより、cTnT陽性率(cTnT陽性細胞数/細胞塊を構成する全細胞数×100)を算出し、心筋純度(%)とした。結果を表4に示す。
分化誘導19日目の細胞の動画を撮影し、任意のスフェロイドのBPM(1分間における拍動数、拍/分)を算出した。結果を表4に示す。
位相差顕微鏡を使用して、それぞれの細胞がスフェロイドを形成している様子を観察した。結果を図2、3に示す。
分化誘導12日目においては、実施例1、2は、比較例1、2に比べて、培養底面の酸素透過度が高いため、細胞増殖率が高く、特に培地高さ10mmの場合に高かった。19日目でも同様の傾向が見られた。また、実施例1、2は、分化誘導12日目、19日目において、比較例1、2よりも心筋純度が高かった。さらに、心筋特異的遺伝子Troponin、MYL2、MYL7の発現を比較したところ、どの遺伝子も比較例1、2に比べて実施例1、2の方が発現量が多く、特に培地高さ10mmの場合に多かった。実施例1、2は、分化誘導19日目において、比較例1、2よりも拍動数が高く、液深さは5mmよりも10mmの方が拍動数が高かった。また、形態観察の結果、実施例1、2では、比較例1、2に比べて、大きさおよび形状が均一である複数のスフェロイドが形成されることが明らかになった。また、実施例1、2では、比較例1、2に比べて、iPS細胞が心筋細胞へと効率よく分化することが明らかになった。
製造例2で作製した培養容器を用い、後述する方法によりヒト骨肉腫由来がん細胞(HOF-143B)を培養し、スフェロイドを形成させた。
培養面の厚さが1000μmである市販のTCPS培養容器(培養面の内径が16mm、24ウェルプレート、コーニング社製、ポリスチレン(PS)製)を使用した以外は、実施例3と同様な方法で培養した。
高酸素透過容器として培養部材の厚さが350μmである市販のPDMS(ポリジメチルシロキサン)製培養容器(培養面の内径が15mm、24ウェルプレート、製品名G-plate、VECELL社製、型番V24WGPB)を使用した以外は、実施例3と同様な方法で培養した。
<細胞の播種>
ヒト骨肉腫由来がん細胞を含む細胞懸濁液を入れた遠沈管(50ml)に培地を加えた。培地は、ウシ胎児血清(Fetal Bovine Serum、FBS、富士フイルム和光純薬)を5mL、200mMのL-グルタミン溶液(富士フィルム和光純薬)を0.5mL、1.5mg/mLのBromo-deoxy Uridine(BUdR)を0.05mL、Non Essential Amino Acid(富士フィルム和光純薬)を0.5mL、E-MEM培地(10mg/mLフェノールレッド、2200mg/mL炭酸水素ナトリウム含有、培養用、富士フイルム和光純薬)を43.95mL加えて調製した。細胞密度の調整は、ヒト骨肉腫由来がん細胞を含む細胞懸濁液の細胞数を調整する方法で実施し、細胞懸濁液0.5mL/ウェルで播種すると細胞密度が1.0×104cells/cm2となるように細胞懸濁液を調製した。
ヒト骨肉腫由来がん細胞を含む細胞懸濁液を培養面にマイクロピペットで播種し、インキュベーターに持ち込み、37℃、5%CO2下で培養を開始した。培養は7日間行った。細胞播種から3日目と6日目に、培地の交換を行った。培地の交換は、培養容器を静置し、スフェロイドが十分に沈降した状態で上清を除去し、除去した分量の培地を追加することにより実施した。
培養7日目に位相差顕微鏡を用いて細胞の形態を観察し、以下の基準で評価した。
A:スフェロイドを形成している
B:細胞が接着し、スフェロイドを形成しない
実施例3を観察した結果を図4に示す。また、評価結果を表5に示す。
比較例3、4では、細胞は培養容器に接着し、スフェロイドを形成しなかったが、実施例3では、細胞がスフェロイドを形成していた。
Claims (12)
- 細胞、組織、または器官をその培養面上で培養する培養部材であり、前記培養部材は4-メチル-1-ペンテン重合体(X)を含み、前記培養面の水接触角が100°より大きく160°以下であり、温度23℃、湿度0%の時の酸素透過度が4500~90000cm3/(m2×24h×atm)である培養部材。
- 前記4-メチル-1-ペンテン重合体(X)が、4-メチル-1-ペンテンとエチレンおよび炭素数3~20のα―オレフィン(4-メチル-1-ペンテンを除く)から選ばれる少なくとも1種の共重合体(x1)である、請求項1に記載の培養部材。
- 前記培養面が、凹凸構造の形成加工を施されていない、請求項1または2に記載の培養部材。
- スフェロイド形成用である、請求項1~3のいずれか1項に記載の培養部材。
- 前記細胞、組織、または器官が、iPS細胞由来の分化細胞を含む、請求項1~4のいずれか1項に記載の培養部材。
- 前記細胞、組織、または器官が、心筋細胞を含む、請求項1~5のいずれか1項に記載の培養部材。
- 前記培養部材の形状がフィルム状またはシート状である、請求項1~6のいずれか1項に記載の培養部材。
- 少なくとも培養面が、請求項1~7のいずれか1項に記載の培養部材で形成された、培養器具。
- 請求項1~7のいずれか1項に記載の培養部材または請求項8に記載の培養器具の培養面に、細胞、組織または器官を接触させる工程(A);および
前記培養面に接触した細胞、組織または器官を培養してスフェロイドを形成させる工程(B);を含む細胞、組織または器官の培養方法。 - さらに、前記細胞等の分化を誘導する工程(C)を含み、工程(C)が、プロテインフリー心筋分化誘導(PFCD)法により、iPS細胞の心筋細胞への分化を誘導する工程である、請求項9に記載の細胞、組織または器官の培養方法。
- 心筋純度を増加させる、請求項9または10に記載の細胞、組織または器官の培養方法。
- 請求項9~11のいずれか1項に記載の培養方法により形成されたスフェロイド。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180084225.8A CN116583595A (zh) | 2020-12-23 | 2021-12-06 | 培养构件及其用途 |
JP2022572073A JPWO2022138101A1 (ja) | 2020-12-23 | 2021-12-06 | |
EP21910251.4A EP4269558A1 (en) | 2020-12-23 | 2021-12-06 | Culture member and use thereof |
KR1020237015272A KR20230079442A (ko) | 2020-12-23 | 2021-12-06 | 배양 부재 및 그 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-213523 | 2020-12-23 | ||
JP2020213523 | 2020-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022138101A1 true WO2022138101A1 (ja) | 2022-06-30 |
Family
ID=82159480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/044665 WO2022138101A1 (ja) | 2020-12-23 | 2021-12-06 | 培養部材およびその用途 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4269558A1 (ja) |
JP (1) | JPWO2022138101A1 (ja) |
KR (1) | KR20230079442A (ja) |
CN (1) | CN116583595A (ja) |
TW (1) | TW202229537A (ja) |
WO (1) | WO2022138101A1 (ja) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
JPH11137241A (ja) * | 1997-11-05 | 1999-05-25 | Otsuka Techno Kk | 培養容器 |
JP2001190267A (ja) * | 2000-01-07 | 2001-07-17 | Mitsui Chemicals Inc | ポリオレフィン樹脂組成物からなる培養容器 |
WO2006054613A1 (ja) | 2004-11-17 | 2006-05-26 | Mitsui Chemicals, Inc. | 固体状チタン触媒成分、オレフィン重合用触媒およびオレフィン系重合体の製造方法 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP2008061609A (ja) | 2006-09-08 | 2008-03-21 | Sumitomo Bakelite Co Ltd | 細胞培養容器の製造方法および細胞培養容器。 |
WO2013111875A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
JP2013169685A (ja) | 2012-02-20 | 2013-09-02 | Mitsui Chemicals Inc | 表面保護フィルム、これを用いた半導体装置の製造方法 |
WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Scivax株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
WO2014050817A1 (ja) | 2012-09-25 | 2014-04-03 | 三井化学株式会社 | オレフィン重合体の製造方法およびオレフィン重合体 |
WO2015182765A1 (ja) | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
WO2016076368A1 (ja) | 2014-11-12 | 2016-05-19 | テルモ株式会社 | 心筋細胞シート |
JP2017077241A (ja) | 2015-10-21 | 2017-04-27 | 株式会社日本触媒 | 接着性細胞培養用基材、ならびにこれを利用した細胞培養容器および細胞培養方法 |
WO2020013345A1 (ja) | 2018-07-11 | 2020-01-16 | 学校法人松本歯科大学 | 親水性の違いを利用したスフェロイドの製造方法 |
WO2020256079A1 (ja) * | 2019-06-21 | 2020-12-24 | 三井化学株式会社 | 培養材およびその用途 |
-
2021
- 2021-12-06 JP JP2022572073A patent/JPWO2022138101A1/ja active Pending
- 2021-12-06 CN CN202180084225.8A patent/CN116583595A/zh active Pending
- 2021-12-06 EP EP21910251.4A patent/EP4269558A1/en active Pending
- 2021-12-06 WO PCT/JP2021/044665 patent/WO2022138101A1/ja active Application Filing
- 2021-12-06 KR KR1020237015272A patent/KR20230079442A/ko unknown
- 2021-12-09 TW TW110145972A patent/TW202229537A/zh unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
JPH11137241A (ja) * | 1997-11-05 | 1999-05-25 | Otsuka Techno Kk | 培養容器 |
JP2001190267A (ja) * | 2000-01-07 | 2001-07-17 | Mitsui Chemicals Inc | ポリオレフィン樹脂組成物からなる培養容器 |
WO2006054613A1 (ja) | 2004-11-17 | 2006-05-26 | Mitsui Chemicals, Inc. | 固体状チタン触媒成分、オレフィン重合用触媒およびオレフィン系重合体の製造方法 |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
JP2008061609A (ja) | 2006-09-08 | 2008-03-21 | Sumitomo Bakelite Co Ltd | 細胞培養容器の製造方法および細胞培養容器。 |
WO2013111875A1 (ja) | 2012-01-27 | 2013-08-01 | 国立大学法人京都大学 | 多能性幹細胞の心筋分化誘導法 |
JP2013169685A (ja) | 2012-02-20 | 2013-09-02 | Mitsui Chemicals Inc | 表面保護フィルム、これを用いた半導体装置の製造方法 |
WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Scivax株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
WO2014050817A1 (ja) | 2012-09-25 | 2014-04-03 | 三井化学株式会社 | オレフィン重合体の製造方法およびオレフィン重合体 |
WO2015182765A1 (ja) | 2014-05-30 | 2015-12-03 | 国立大学法人京都大学 | 低分子化合物を用いた多能性幹細胞の心筋分化誘導法 |
WO2016076368A1 (ja) | 2014-11-12 | 2016-05-19 | テルモ株式会社 | 心筋細胞シート |
JP2017077241A (ja) | 2015-10-21 | 2017-04-27 | 株式会社日本触媒 | 接着性細胞培養用基材、ならびにこれを利用した細胞培養容器および細胞培養方法 |
WO2020013345A1 (ja) | 2018-07-11 | 2020-01-16 | 学校法人松本歯科大学 | 親水性の違いを利用したスフェロイドの製造方法 |
WO2020256079A1 (ja) * | 2019-06-21 | 2020-12-24 | 三井化学株式会社 | 培養材およびその用途 |
Non-Patent Citations (17)
Title |
---|
BURRIDGE ET AL., CELL STEM CELL, vol. 10, no. 1, 6 January 2012 (2012-01-06), pages 16 - 28 |
H. KAWASAKI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 1580 - 1585 |
H. SUEMORI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 345, 2006, pages 926 - 932 |
H. SUEMORI ET AL., DEV. DYN., vol. 222, 2001, pages 273 - 279 |
J. YU ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920 |
K. TAKAHASHI ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
K. TAKAHASHIS. YAMANAKA, CELL, vol. 126, 2006, pages 663 - 676 |
KATTMAN ET AL., CELL STEM CELL, vol. 8, 2011, pages 228 - 240 |
KLIMANSKAYA I, NATURE, vol. 444, 2006, pages 481 - 485 |
LIAN ET AL., NAT PROTOC, vol. 8, 2013, pages 162 - 175 |
M. UENO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 9554 - 9559 |
MICHALJANIčOVÁ I.; SLEPIčKA P.; SLEPIčKOVÁ KASÁLKOVÁ N.; SAJDL P.; : "Plasma and laser treatment of PMP for biocompatibility improvement", VACUUM., PERGAMON PRESS., GB, vol. 107, 1 January 1900 (1900-01-01), GB , pages 184 - 190, XP028865850, ISSN: 0042-207X, DOI: 10.1016/j.vacuum.2014.01.023 * |
MINAMI ET AL., CELL REP, vol. 2, no. 5, 2012, pages 1448 - 1460 |
NAKAGAWA, M ET AL., NAT. BIOTECHNOL., vol. 26, 2008, pages 101 - 106 |
THOMSON JA ET AL., PROC NATL. ACAD., vol. 92, 1995, pages 7844 - 7848 |
THOMSON JA ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147 |
ZHANG ET AL., CIRC RES, vol. 111, 2012, pages 1125 - 1136 |
Also Published As
Publication number | Publication date |
---|---|
KR20230079442A (ko) | 2023-06-07 |
CN116583595A (zh) | 2023-08-11 |
JPWO2022138101A1 (ja) | 2022-06-30 |
EP4269558A1 (en) | 2023-11-01 |
TW202229537A (zh) | 2022-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114807035B (zh) | 临床级别视网膜色素上皮细胞的可再现的分化方法 | |
JP6986016B2 (ja) | Macsを用いた幹細胞由来網膜色素上皮の精製 | |
CN110945119B (zh) | 包含连续上皮的视网膜组织的成熟方法 | |
CN114717183A (zh) | 多能干细胞制造系统和生产诱导多能干细胞的方法 | |
JP6826244B1 (ja) | 培養材およびその用途 | |
KR20170072941A (ko) | 망막 조직의 제조 방법 | |
WO2019054514A1 (ja) | 網膜組織の製造方法 | |
Rumiński et al. | Osteogenic differentiation of human adipose-derived stem cells in 3D conditions-comparison of spheroids and polystyrene scaffolds | |
WO2018116904A1 (ja) | 細胞培養基材 | |
CN111094548A (zh) | 基于背侧化信号转导物质或腹侧化信号转导物质的增加视锥细胞或视杆细胞的方法 | |
Lin et al. | Integrated generation of induced pluripotent stem cells in a low-cost device | |
US11499136B2 (en) | Cell culture substrate | |
WO2022138101A1 (ja) | 培養部材およびその用途 | |
WO2021145402A1 (ja) | 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用 | |
WO2017078007A1 (ja) | 培養容器 | |
JP2022157708A (ja) | 多能性幹細胞の分化方法 | |
EP3712243A1 (en) | Liquid set for droplet discharging apparatus | |
JP7267607B2 (ja) | 細胞培養装置、培養液アスピレータ及び細胞培養方法 | |
Harata et al. | Improving chondrocyte harvests with poly (2-hydroxyethyl methacrylate) coated materials in the preparation for cartilage tissue engineering | |
JPWO2004078961A1 (ja) | 浮遊担体および浮遊・回収方法 | |
Hoss et al. | Expansion and differentiation of germline-derived pluripotent stem cells on biomaterials | |
Khaseb et al. | Expression analysis of genes involved in the expansion of hematopoietic stem cells (SCF, Flt3-L, TPO, IL-3, and IL-6) in unrestricted somatic stem cells cultured on fibrin | |
JP2022154850A (ja) | 心筋細胞の培養方法 | |
JP2015047083A (ja) | 細胞凝集塊の製造方法、及び薬剤のスクリーニング方法 | |
EP4130238A1 (en) | Hepes-containing medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21910251 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20237015272 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022572073 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084225.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021910251 Country of ref document: EP Effective date: 20230724 |